Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the invention described herein pertains to compounds, and compositions, methods, and uses thereof, for treating brain injuries.
• the invention described herein pertains to vasopressin receptor modulators, and compositions, methods, and uses thereof, for treating brain injury.
• TBI traumatic brain injury
• Cerebral edema often termed the secondary injury in TBI, follows the primary insult and is a major contributor to morbidity and mortality. Left untreated, brain injury can also lead to severe cognitive, learning, and memory impairment. In addition, brain injuries can lead to loss of motor function. Cerebral edema can result from brain trauma as well as other nontraumatic causes such as ischemic stroke, cancer, and brain inflammation that may arise from other diseases or conditions, such as meningitis or encephalitis. A treatment that mitigates or prevents the effects of moderate to severe TBI, including closed head, non-penetrating, moderate TBIs that result from single incidents, such as car accidents, falls, and the like is needed to fill this critical gap in care. Accordingly, there is a current need for compounds, compositions, and methods for treating brain injury.
• VlaR vasopressin Via receptor
• Arginine vasopressin is a chemical signal in the brain influencing suggested herein that AVP is a chemical signal in the brain influencing cerebral vascular resistance and brain water permeability and may contribute to the pathophysiology following head trauma or injury. These cerebrovascular effects are mediated through the VlaR receptor, which is highly expressed in cortical and subcortical brain areas across all mammals. However, it has been reported that the systemic treatment of brain injury is complicated by unwanted side effects arising from competing antagonism of peripheral VlaR receptors, such as decreases in cerebral blood flow, blood pressure, or other loss of cardiovascular function. Krieg et al., J. Neurotrauma 32:221-27 (2015).
• the compounds described herein can be administered systemically, including oral administration at doses that are therapeutically effective in the central nervous system (CNS), without clinically significant adverse affects on blood pressure or cardiovascular function.
• CNS central nervous system
• selective VlaR antagonists, and compositions and methods for using such vasopressin antagonists are described herein.
• selective VlaR antagonists, and compositions and methods for using such VlaR antagonists, that are configured to achieve or capable of generating CNS concentrations in the range from 1 nM to at least about 100 nM upon administration to a host animal are described herein.
• selective VlaR antagonists, and compositions and methods for using such VlaR antagonists, that are configured to achieve or capable of generating CNS concentrations in the range from 1 nM to at least about 10 nM, or at least about 1 nM upon administration to a host animal are described herein.
• VlaR antagonists in another illustrative embodiment, highly potent and selective VlaR antagonists, and compositions and methods for using such VlaR antagonists, that are configured to achieve or capable of generating CNS concentrations of at least about 100 pM, at least about 10 pM, or at least about 1 pM, upon administration to a host animal are described herein.
• VlaR antagonists described herein are of the formula
• A is a carboxylic acid, an ester, or an amide
• , . , , , b is a carboxylic acid, an ester, or an amide
• B is an alcohol or tnioi, or a derivative thereof, including alkyl, aryl, or acyl derivatives thereof;
• R 1 is hydrogen or C1-C6 alkyl
• R 2 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halo, haloalkyl, cyano, formyl, alkylcarbonyl, or a substituent selected from the group consisting
• R 8 and R 8 ' are each independently selected from hydrogen, alkyl, cycloalkyl, optionally substituted aryl, or optionally substituted arylalkyl; or R 8 and R 8 ' are taken together with the attached nitrogen atom to form a heterocyclyl group; and where R 9 is selected from hydrogen, alkyl, cycloalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, and R 8 R 8' N-(Ci-C 4 alkyl);
• R 3 is an amino, amido, acylamido, or ureido group, which is optionally substituted; or R 3 is a nitrogen-containing heterocyclyl group attached at a nitrogen atom; and
• R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcarbonyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted arylhaloalkyl, optionally substituted arylalkoxyalkyl, optionally substituted arylalkenyl, optionally substituted arylhaloalkenyl, or optionally substituted arylalkynyl.
• compositions containing one or more of the compounds are also described herein.
• the compositions include a therapeutically effective amount of the one or more compounds for treating a host animal with a brain injury.
• the compositions may include other components and/or ingredients, including, but not limited to, other therapeutically active compounds, and/or one or more carriers, diluents, excipients, and the like, and combinations thereof.
• methods for using the compounds and pharmaceutical compositions for treating host animals with a brain injury are also described herein. In one aspect, the methods include the step of administering one or more of the compounds and/or compositions described herein to the host animal.
• the methods include administering a therapeutically effective amount of the one or more compounds and*Or compositions described herein for treating host animals a brain injury.
• uses of the compounds and compositions in the manufacture of a medicament for treating host animals with a brain injury are also described herein.
• the medicaments include a therapeutically effective amount of the one or more compounds and/or compositions described herein.
• the compounds described herein may be used alone or in combination with other compounds useful for treating brain injuries, including those compounds that may be therapeutically effective by the same or different modes of action.
• the compounds descnbed herein may De used in combination with other compounds that are administered to treat other symptoms of a brain injury, such as pain, inflammation, nausea, vomiting, blurred vision, faintness, and the like.
• FIG. 1 shows results for the Novel Object Recognition Test
• FIG. 2A shows results for the Barnes Maze Test; Control Group (CG). Injury Group (IG), Treatment Group (TG); * (p ⁇ 0.05), ** (p ⁇ 0.01).
• FIG. 2B shows results for the Barnes Maze Test broken down by days; Control Group ( ⁇ ), Injury Group (o), Treatment Group ( ⁇ ); * (p ⁇ 0.05), ** (p ⁇ 0.01).
• FIG. 3 shows Resting State Functional Connectivity comparing the Injury Group to the Treatment Group.
• FIG. 4A shows glass brains showing the 3D organizations of the hypoconnectivity observed in the Injury Group for Area G.
• FIG. 4B shows glass brains showing the 3D organizations of the hy perconnectivity observed in the Treatment Group for Area G.
• FIG. 5 shows scans and volumes of lateral ventricles; Control Group (CG), Injury Group (IG), Treatment Group (TG).
• CG Control Group
• IG Injury Group
• TG Treatment Group
• FIG. 6 shows glass brains showing the 3D organizations of the hypoconnectivity observed in the Injury Group and Treatment Group for Area M.
• Described herein is the use of one or more VI aR antagonists for treating brain injuries.
• the compounds described herein may have the potential to greatly improve the lives of those suffering from brain injuries, including, but not limited to traumatic brain injury (TBI), including blast TBI, cerebral edema, chronic traumatic encephalopathy (CTE), subarachnoid hemorrhage, stroke, concussion, and falls.
• TBI traumatic brain injury
• CTE chronic traumatic encephalopathy
• subarachnoid hemorrhage stroke, concussion, and falls.
• a method for treating a brain injury in a host animal comprises administering a composition comprising one or more selective VlaR antagonists described herein to the host animal.
• a method for treating a brain injury in a host animal is described, where the brain injury is caused at least in part by impact, traumatic brain injury (TBI), mild TBI, blast TBI, cerebral edema, chronic traumatic encephalopathy (CTE), subarachnoid hemorrhage, , , ⁇ , c , , stroke, lscnemic stroke, concussion, tails, or a combination thereot, and where tne metnoa comprises administering a composition comprising one or more selective VlaR antagonists described herein to the host animal.
• TBI traumatic brain injury
• CTE chronic traumatic encephalopathy
• subarachnoid hemorrhage , , ⁇ , c , , stroke, lscnemic stroke, concussion, tails, or a combination thereot
• tne metnoa comprises administering a composition comprising one or more selective VlaR antagonists described herein to the host animal.
• edema such as lateral ventricle edema, cognitive deficits, learning deficits, memory deficits, or motor deficits, or a combination of any of the foregoing.
• A is a carboxylic acid, an ester, or an amide
• B is a carboxylic acid, an ester, or an amide; or B is an alcohol or thiol, or a derivative thereof;
• R 1 is hydrogen or Ci-Cs alkyl
• R 2 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halo, haloalkyl, cyano, formyl, alkylcarbonyl, or a substituent selected from the group consisting
• R 8 and R 8' are each independently selected from hydrogen, alkyl, cycloalkyl, optionally substituted aryl, or optionally substituted arylalkyl; or R 8 and R 8' are taken together with the attached nitrogen atom to form a heterocyclyl group; and where R 9 is selected from hydrogen, alkyl, cycloalkyl, alkoxyalky 1, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, and R 8 R 8 'N-(Ci-C 4 alkyl);
• R 3 is an amino, amido, acylamido, or ureido group, which is optionally substituted; or R 3 is a nitrogen-containing heterocyclyl group attached at a nitrogen atom; and
• R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcarbonyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted arylhaloalkyl, optionally substituted arylalkoxyalkyl, optionally substituted arylalkenyl, optionally substituted arylhaloalkenyl, or optionally substituted arylalkynyl.
• a and A' are each independently selected from -CO2H, or an ester or amide derivative thereof;
• n is an integer selected from 0 to about 3;
• R 1 is hydrogen or C1-C6 alkyl
• R 2 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halo, haloalkyl, cyano, formyl, alkylcarbonyl, or a substituent selected from the group consisting
• R 8 and R 8 ' are each independently selected from hydrogen, alkyl, cycloalkyl, optionally substituted aryl, or optionally substituted arylalkyl; or R 8 and R 8 ' are taken together with the attached nitrogen atom to form an heterocycle; and where R 9 is selected from hydrogen, alkyl, cycloalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, and R 8 R 8' N-(Ci-C 4 alkyl);
• R 3 is an amino, ami do, acylamido, or ureido group, which is optionally substituted; or R 3 is a nitrogen-containing heterocyclyl group attached at a nitrogen atom; and is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcarbonyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted arylhaloalkyl, optionally substituted arylalkoxyalkyl, optionally substituted arylalkenyl, optionally substituted arylhaloalkenyl, or optionally substituted arylalkynyl.
• A is -CO2H, or an ester or amide derivative thereof
• Q is oxygen; or Q is sulfur or disulfide, or an oxidized derivative thereof;
• n is an integer from 1 to 3; ⁇ ⁇ , ⁇ . _ , . . , ⁇ ,
• R 5" is selected from hydrogen, alkyl, cycloalkyl, alkoxyalkyl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted
• heterocyclylalkyl and optionally substituted aminoalkyl.
• A is -CO2R 5 ; where R 5 is selected from hydrogen, alkyl, cycloalkyl, alkoxyalkyl, optionally substituted arylalkyl, heterocyclyl, heterocyclyl(Ci-C4 alkyl), and R 6 R 7 N-(C 2 -C4 alkyl).
• heterocyclyl is independently selected from tetrahydrofuryl, morpholinyl, pyrrolidinyl, piperidinyl piperazinyl, homopiperazinyl, or quinuclidinyl; where said morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, or quinuclidinyl is optionally N-substituted with C1-C4 alkyl or optionally substituted aryl(Ci-C4 alkyl). It is to be understood that in each occurrence of the various embodiments described herein, heterocyclyl is independently selected in each instance.
• R 6 is independently selected from hydrogen or alkyl; and R 7 is independently selected in each instance from alkyl, cycloalkyl, optionally substituted aryl, or optionally substituted arylalky l.
• R 6 and R 7 are taken together with the attached nitrogen atom to form an optionally substituted heterocycle, such as pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and homopiperazinyl; where said piperazinyl or homopiperazinyl is also optionally N-substituted with R 13 ; where R 13 is independently selected in each instance from hydrogen, alkyl, cycloalkyl, alkoxycarbony l, optionally substituted aryloxycarbonyl, optionally substituted arylalkyl, and optionally substituted aryloyl.lt is also to be understood that in each occurrence of the various embodiments described herein, R 6 and R 7 are each independently selected in each instance.
• R 6 and R 7 are each independently selected in each instance.
• A is an amide.
• A is an amide of a secondary amine, also refered to herein as a secondary amide. ,. . , . .. . .
• the antagonists are diesters. acid-esters, or diacids, including pharmaceutically acceptable salts thereof, where each of A and A' is independently selected.
• the method of any one of the preceding clauses wherein the antagonists are ester-amides, where one of A and A' is an ester, and the other is an amide.
• the method of any one of the preceding clauses wherein the antagonists are diamides, where each of A and A' are independently selected from monosubstituted amido, disubstituted amido, and optionally substituted nitrogen-containing heterocyclylamido.
• a and/or A' is an independently selected monosubstituted amido of the formula C(0)NHX-, where X is selected from alkyl, cycloalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, heterocyclyl, heterocyclyl-(Ci-C4 alkyl), R 6 R 7 N-, and R 6 R 7 N-(C 2 -C4 alkyl), where each heterocyclyl is independently selected.
• a and/or A' is an independently selected disubstituted amido of the formula C(0)NR 14 X-, where R 14 is selected from hydroxy, alkyl, alkoxycarbonyl, and benzyl; and X is selected from alkyl, cycloalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, heterocyclyl, heterocyclyl-(Ci-C4 alkyl), R 6 R 7 N-, and R 6 R 7 N-(C2-C4 alkyl), where each heterocyclyl is independently selected.
• a and/or A' is an amide of an independently selected optionally substituted nitrogen-containing heterocycle attached at a nitrogen.
• nitrogen-containing heterocycles include but are not limited to pyrrolidinyl, pyrrohdinonyl, piperidinyl, piperidinonyl, piperazinyl, homopiperazinyl, triazolidinyl, triazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,3-oxazinyl, morpholinyl, oxadiazolidinyl, thiadiazohdinyl, and 1,2,3,4-tetrahydroisoquinolin- 2-yl; each of which is optionally substituted.
• Such optional substitutions include the groups R 10 , R 12 , R 6 R 7 N-, and R 6 R 7 N-(
• a and/or A' is independently optionally substituted 2-(pyrrolidin-l-ylmethyl)pyrrolidin-l-yl attached at a nitrogen.
• a and/or A' is independently optionally substituted l,2,3,4-tetrahydroisoquinolin-2-yl attached at a nitrogen.
• a and/or A' is an independently selected amide of an optionally substituted piperidinyl attached at the nitrogen.
• Illustrative optional substitutions include hydroxy, alkyl, cycloalkyl, alkoxy, alkoxycarbonyl, hydroxyalkyloxyalkyl, including (hydroxy(C 2 -C4 alkyloxy))-(C 2 -C4 alkyl), R 6 R 7 N-, R 6 R 7 N- n n xT ,
• alkyl include ing R 6 R N-(Ci-C4 alkyl), diphenylmethyl, optionally substitute aryi, optionally substituted aryl(Ci-C4 alkyl), and piperidin-l-yl(Ci-C4 alkyl).
• a and/or A' is an independently selected piperidinyl substituted at the 4-position and attached at the nitrogen.
• a and/or A' is an independently selected amide of an optionally substituted piperazinyl attached at a nitrogen.
• Illustrative optional substitutions include hydroxy, alkyl, cycloalkyl, alkoxy, alkoxycarbonyl, hydroxyalkyloxyalkyl, including (hydroxy(C 2 -C4 alkyloxy))-(C2-C4 alkyl), R 6 R 7 N-, R 6 R 7 N- alkyl, including R 6 R 7 N-(Ci-C4 alkyl), diphenylmethyl, optionally substituted aryl, optionally substituted aryl(Ci-C4 alkyl), and piperidin- 1 -y 1(C i-C 4 alkyl).
• a and/or A' is an independently selected piperazinyl substituted at the 4-position and attached at a nitrogen.
• a and/or A' is an independently selected amide of an optionally substituted homopiperazinyl attached at a nitrogen.
• Illustrative optional substitutions include hydroxy, alkyl, cycloalkyl, alkoxy, alkoxycarbonyl, hydroxyalkyloxyalkyl, including (hydroxy(C2-C4 alkyloxy))-(C2-C4 alkyl), R 6 R 7 N-, R 6 R 7 N-alkyl, including R 6 R 7 N-(Ci-C4 alkyl), diphenylmethyl, optionally substituted aryl, optionally substituted aryl(Ci-C4 alkyl), and pip eri din- 1 -y 1 (C i -C 4 alkyl).
• a and/or A' is an independently selected
• a and/or A' is an independently selected homopiperazinyl substituted at the 4-position with alkyl, aryl, aryl(Ci-C4 alkyl), and attached at a nitrogen.
• A' is monosubstituted amido, disubstituted amido, or an optionally substituted nitrogen-containing heterocyclylamido.
• A' is -CO2R 5 ; where R 5' is selected from hydrogen, alkyl, cycloalkyl, alkoxyalkyl, optionally substituted arylalkyl, heterocyclyl, heterocyclyl(Ci-C4 alkyl), and R 6 R 7 N-(C2-C4 alkyl); where heterocyclyl is in each occurrence independently selected from tetrahydrofuryl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, or quinuclidinyl; where said morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, or quinuclidinyl is
• R ⁇ is hydrogen or optionally substituted alkyl, or an amide prodrug forming group
• R a is hydrogen or optionally substituted alkyl
• R ⁇ r is hydrogen or one or more aryl substituents, such as but not limited to halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, nitro, and the like.
• A is of the formula
• R N , R a , and R Ar are as defined herein.
• A is selected from monosubstituted amido, disubstituted amido, and optionally substituted nitrogen-containing heterocyclylamido.
• A is an amide of optionally substituted 1-tetrahydronaphthylamme.
• a and/or A is a monosubstituted amido of the formula C(0)NHX, where X is selected from alkyl, cycloalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, heterocyclyl, heterocyclyl-(Ci-C4 alkyl), R 6 R 7 N-, and R 6 R 7 N-(C2-C4 alkyl), where each heterocyclyl is independently selected.
• a and/or A is a disubstituted amido of the formula C(0)NR 14 X, where R 14 is selected from hydroxy, alkyl, alkoxy carbonyl, and benzyl; and X is selected from alkyl, cycloalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, heterocyclyl, heterocyclyl-(Ci-C4 alkyl), R 6 R 7 N- and R 6 R 7 N-(C2-C4 alkyl), where each heterocyclyl is independently selected.
• a and/or A is an amide of an optionally substituted nitrogen-containing heterocycle attached at a nitrogen.
• nitrogen-containing heterocycles include but are not limited to pyrrolidinyl, pyrrolidinonyl, piperidinyl, pipendinonyl, piperazinyl, homopiperazinyl, triazolidinyl, triazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,3-oxazinyl, morpholinyl, oxadiazolidinyl, thiadiazolidinyl, and l,2,3,4-tetrahydroisoquinolin-2-yl; each of which is optionally substituted.
• Such optional substitutions include the groups R 10 , R 12 , R 6 R 7 N-, and ,, , , , ,
• a and/or A is an amide of an optionally substituted piperidinyl attached at the nitrogen.
• Illustrative optional substitutions include hydroxy, alkyl, cycloalkyl, alkoxy, alkoxycarbonyl,
• hydroxyalkyloxyalkyl including (hydroxy(C2-C4 alkyloxy))-(C2-C4 alkyl), R 6 R 7 N- R 6 R 7 N- alkyl, including R 6 R 7 N-(Ci-C 4 alkyl), diphenylmethyl optionally substituted aryl, optionally substituted aryl(Ci-C4 alkyl), and piperidin-l-yl(Ci-C4 alkyl).
• a and/or A is an amide of an optionally substituted piperazinyl attached at a nitrogen.
• Illustrative optional substitutions include hydroxy, alkyl, cycloalkyl, alkoxy, alkoxycarbonyl, hydroxyalkyloxyalkyl, including (hydroxy(C 2 -C 4 alkyloxy))-(C2-C 4 alkyl), R 6 R 7 N-, R 6 R 7 N-alkyl. including R 6 R 7 N-(Ci-C 4 alkyl), diphenylmethyl, optionally substituted aryl, optionally substituted aryl(Ci-C4 alkyl), and piperidin-l-yl(Ci-C4 alkyl).
• a and/or A' is piperazinyl substituted at the 4-position and attached at a nitrogen.
• a and/or A is an amide of an optionally substituted homopiperazinyl attached at a nitrogen.
• Illustrative optional substitutions include hydroxy, alkyl, cycloalkyl, alkoxy, alkoxycarbonyl,
• hydroxyalkyloxyalkyl including (hydroxy(C2-C4 alkyloxy))-(C 2 -C4 alkyl), R 6 R 7 N- ; R 6 R 7 N- alkyl, including R 6 R 7 N-(Ci-C4 alkyl), diphenylmethyl, optionally substituted aryl, optionally substituted aryl(Ci-C4 alkyl), and piperidin-l-yl(Ci-C4 alkyl).
• a and/or A' is homopiperazinyl substituted at the 4-position and attached at a nitrogen.
• a and/or A' is homopiperazinyl substituted at the 4-position with alkyl, aryl, aryl(Ci-C4 alkyl), and attached at a nitrogen.
• a and/or A is an amide of a heterocycle attached at a nitrogen, where the heterocycle is substituted with heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl.
• a and/or A is an amide of an optionally substituted benzyl, optionally substituted 1-naphthylmethyl, or optionally . . . . ⁇ . . . . . . .
• substitutions include, but are not limited to, 1,5- dichloro, 2,5-dichloro, 2,5-dimethoxy, 2-trifluoromethyl, 2-fluoro-3-trifluoromethyl, 2-fluoro- 5-trifluoromethyl, 2-methyl, 2-methoxy, 3,4-dichloro, 3,5-ditrifluoromethyl, 3,5-dichloro, 3,5- dimethyl, 3.5-difluoro, 3,5-dimethoxy, 3-bromo, 3-trifluoromethyl, 3-chloro-4-fluoro, 3-chloro, 3-fluoro-5-trifluoromethyl, 3-fluoro, 3-methyl, 3-nitro, 3-trifluoromethoxy, 3-methoxy, 3- phenyl, 4-trifluoromethyl, 4-chloro-3-trifluoromethyl, 4-fluoro-3-trifluoromethyl, 4-methyl, and the like.
• a and/or A is an amide of an optionally substituted benzyl-N-methylamine.
• a in formula (I) or (II) is an amide of an optionally substituted benzyl-N-butylamine, including n-butyl, and t-butyl.
• A is an amide of an optionally substituted benzyl-N-benzylamine.
• Optional substitutions include, but are not limited to, 2,3- dichloro, 3,5-dichloro, 3-bromo, 3-trifluoromethyl, 3-chloro, 3-methyl, and the like.
• a and/or A is an amide of an optionally substituted 1-phenylethyl, 2-phenylethyl, 2-phenylpropyl, or
• a and/ or A' is an amide of an optionally substituted 1-phenylethyl, 2-phenylethyl, 2-pheny lpropyl,
• a and/or A' is an amide of an optionally substituted 2-phenyl- -alanine, or derivative thereof, 1 -phenylpropanolamine, and the like.
• Optional substitutions include, but are not limited to, 3-trifluoromethoxy, 3-methoxy, 3,5-dimethoxy, 2-methyl, and the like.
• a and/or A is an amide of an optionally substituted 1-phenylcyclopropyl, 1-phenylcyclopentyl, or
• 1-phenylcyclohexylamine 1-phenylcyclohexylamine.
• Optional substitutions include, but are not limited to, 3-fluoro, 4- methoxy, 4-methyl, 4-chloro, 2-fluoro, and the like.
• a and/or A is an amide of an optionally substituted heteroary lmethylamine, including but not limited to 2-furyl, 2- thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and the like.
• Optional substitutions include, but are not limited to, 5-methyl, 3-chloro, 2-methyl, and the like.
• a and/or A is an amide of a partially saturated bicyclic aryl, including but not limited to 1-, 2-, 4-, and 5-indanylamine, 1- and 2-tetrahydronaphthylamine, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like, each of which is optionally substituted.
• neterocyciyi neterocyclylalkyl, optionally substituted aryl, and optionally substituted arylalKyl.
• Piperidines and piperazines include the formulae:
• A' is an amide of a substituted heterocycle attached at nitrogen.
• Substituents include alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, and arylalkyl.
• A' is an amide of a heterocy cle attached at nitrogen substituented with alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, or heterocyclylalkyl.
• A' is an amide of an optionally substituted arylheterocyclylamine, aiylalkylheterocyclylamine,
• heterocyclylalkylamine or heteroarylalkylamine.
• A' is an amide of piperi din- 1-ylpiperi dine or piperi din- 1-ylalkylpiperi dine.
• alkyl is Ci -C2-alkyl.
• A is an amide of a substituted piperi dine or piperazine.
• B is an alcohol or thiol, or a derivative thereof, including alkyl, aryl, or acyl derivatives thereof.
• R 5" is optionally substituted aryl(C2-C4 alkyl).
• R 5" is optionally substituted aryl(Ci -C2 alkyl).
• R 5" is optionally substituted benzyl.
• R 5" is optionally substituted alkyl.
• R 10 and R 11 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, alkoxycarbonyl, alkylcarbonyloxy, optionally substituted aryl optionally substituted arylalkyl, optionally substituted arylalkyloxy, optionally substituted arylalkylcarbonyloxy, diphenylmethoxy, triphenylmethoxy, and the like; and R 12 is selected from hydrogen, alkyl, cycloalkyl, alkoxycarbonyl, optionally substituted
• aryloxycarbonyl optionally substituted arylalkyl, optionally substituted aryloyl, and the like.
• R 10 . R 11 . and R 12 are as defined herein
• R 10 , R 11 , and R 12 are as defined herein.
• R 10 and R 11 are as defined herein.
• R 10 is alkyl, aryl, or arylalkyl, each of which is optionally substituted, or wherein R 10 is optionally substituted aryl.
• Y an electron withdrawing group, such as halo
• ⁇ is hydrogen or one or more aryl substituents, such as but not limited to halo, hydroxy, amino, nitro, optionally substituted alkyl, optionally substituted alkoxy, and the like.
• the double bond in the formulae may be all or substantially all (E), all or substantially all (Z), or a mixture thereof.
• the method of any one of the preceding clauses wherein the double bond in the formulae is all or substantially all (E).
• R 4 is of the formulae:
• ⁇ is as defined herein. In another embodiment, ⁇ is not hydrogen.
• n 1, the stereochemistry of the a-carbon is (S) or (R), or is an epimeric mixture.
• the method of any one of the preceding clauses wherein n is 1 and Q is oxygen, the stereochemistry of the a-carbon is (R).
• vasopressin Via receptor binding affinity IC50
• IC50 vasopressin Via receptor binding affinity
• the administration step includes a total daily dose of about 160 to about 700 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form.
• the administration step includes a total daily dose of about 160 to about 500 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form.
• the administration step includes a total daily dose of about 160 to about 400 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form.
• the administration step includes a total daily dose of about 160 to about 320 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form.
• the administration step includes a total daily dose of about 160 to about 240 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form. ,. . , . .. . .
• rapid or immediate release oral administration and/or parenteral administration will provide a high Cmax with a very short Tmax.
• rapid or immediate release oral administration and/or parenteral administration will avert downstream damage caused by injury to the brain that is left untreated, such as secondary injury events arising from cellular processes and biochemical cascades that occur in the minutes to days following the trauma.
• Secondary injury events include damage to the blood-brain barrier, release of factors that cause inflammation, free radical overload, excitotoxicity (excessive release of the neurotransmitter glutamate), influx of calcium and sodium ions into neurons, dysfunction of mitochondria, injured axons in the brain's white matter separating from their cell bodies, changes in the blood flow to the brain, including ischemia, cerebral hypoxia, cerebral edema, and raised intracranial pressure.
• the administration step includes a b.i.d. dosing protocol.
• a pharmaceutical composition adapted for or capable of treating a brain injury or disorder in a host animal comprising one or more compounds of any one of the foregoing clauses, and optionally, one or more carriers, diluents, or adjuvants, or a combination thereof.
• a unit dose or unit dosage form adapted for or capable of treating a brain injury or disorder in a host animal the composition comprising one or more compounds of any one of the foregoing clauses, and optionally, one or more carriers, diluents, or adjuvants, or a combination thereof.
• the unit dose or unit dosage form of any one of the preceding clauses comprising about 80 to about 350 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form. ,. . , . , .
• the unit dose or unit dosage form of any one of the preceding clauses comprising about 80 to about 200 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form.
• the unit dose or unit dosage form of any one of the preceding clauses comprising about 80 to about 160 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form.
• the unit dose or unit dosage form of any one of the preceding clauses comprising about 80 to about 120 mg total of one or more compounds of any one of the foregoing clauses, in single or divided form.
• R N , R A , and R AR are as defined herein; and n
• R N , R A , and R AR are as defined herein; n is 1; and R 1 is hydrogen;
• R1 and R 3 are both hydrogen
• R 1 and R 2 are both hydrogen; and R is of the formula
• R 10 , R 11 , and R 12 are as defined herein;
• R ⁇ R A , and R ⁇ R are as defined herein; n is 1; R1 and R 2 are both hydrogen; and R ⁇ is of the formula
• R 10 and R 11 are as defined herein;
• R N , R A , and R ⁇ R are as defined herein; n is 1; R 1 and R 2 are both hydrogen; and A' is of the formula
• a anavor A may include a chiral center, either ol the optically pure enannomers may De included in the compounds described herein; alternatively, the racemic form may be used.
• either or both of the following enatiomers may be included in the compounds described herein (R)-l-(3-methoxyphenyl)ethylamine, (R)-l-(3- trifluoromethylphenyl)ethylamine, (R)-l,2,3,4-tetrahydro-l-naphthylamine, (R)-l- indanylamine, (R)-a,N-dimethylbenzylamine, (R)-a-methylbenzylamine, (S)-l-(3- methoxyphenyl)ethylamine, (S)-l-(3-trifluoromethylphenyl)ethylamine, (S)-l,2,3,4-tetrahydro- 1-naphth
• compounds described herein cross the blood-brain- barrier (BBB) and show high CNS permeability.
• BBB blood-brain- barrier
• compounds described herein show efficacious dose levels in the brain for treating brain injuries.
• compounds described herein exhibit plasma levels at or in excess of those necessary for clinical efficacy in treating brain injuries.
• compounds described herein exhibit pharmacokinetics consistent with twice per day (b.i.d.) dosing.
• compounds described herein exhibit pharmacokinetics consistent with once per day (q.d.) dosing. It is appreciated herein that both b.i.d. and q.d. dosing may be an important feature in improving patient compliance, leading to overall enhanced clinical effectiveness.
• compounds described herein are metabolically stable in stomach and blood.
• compounds described herein exhibit
• compounds described herein exhibit respiratory safety in vivo.
• compounds described herein, and pharmaceutical compositions and medicaments containing them exhibit high plasma levels and high brain levels, including with oral administration.
• compounds described herein, and pharmaceutical compositions and medicaments containing them capable of crossing the blood brain barrier (BBB), including with oral administration.
• BBB blood brain barrier
• compounds described herein, and pharmaceutical compositions and medicaments containing them exhibit high CNS bioavailability and high affinity without significant or competitive binding to other predetermined GPCRs, or other predetermined receptors, including but not limited to neurotransmitter related receptors, steroid receptors, ion channels, second messenger receptors, prostaglandin receptors, growth factor and hormone receptors, other brain and gastrointestinal tract peptide receptors, other enzymes, and the like.
• compounds described herein, and pharmaceutical compositions and medicaments containing them are inactive or substantially inactive at 100 nM against a standard panel of 64 receptors including 35 GPCRs (Novascreen panel), including neurotransmitter related receptors, steroidal , ,
• receptors ion cnannels, second messenger receptors, prostaglandin receptors, growtn tactor receptors, hormonal receptors, brain/gut peptides (not including vasopressin 1), and enzymes.
• AVP and related peptides represent a family of chemical signals in vertebrates and serve an important function in the control of social behaviors and emotions.
• AVP is synthesized in neurons in the hy pothalamus of all mammals. It is released from nerve endings in the median eminence and transported to the pituitary gland, where it enhances the release of adrenocorticotrophic hormone (ACTH) and ultimately the level of stress hormones in the circulation through its actions at pituitary AVP receptors. From nerve endings in the pituitary, AVP also enters the general blood stream where it acts on the heart and blood vessels to affect cardiac performance and on the kidneys to decrease urine volume.
• ACTH adrenocorticotrophic hormone
• AVP neurons and nerve fibers also are found throughout the limbic system of the brain. AVP exerts its physiological and behavioral effects by binding to specific G-Protein Coupled Receptors (GPCRs) in the central nervous system and certain peripheral tissues/sites.
• GPCRs G-Protein Coupled Receptors
• Vlb receptor Three distinct AVP receptor subtypes have been identified ⁇ Via, Vlb, and V2.
• Via is the predominant AVP receptor found in the limbic system and cortex, Vlb receptor is located in limbic sy stem and pituitary gland, although it is less widespread than Via.
• the V2 receptor is localized in kidney, where it mediates the antidiuretic effects of vasopressin. It is generally believed herein that V2 is not expressed in the nervous systems of adult animals or humans.
• compounds described herein are selectively active at the Via AVP receptor, and are less active, substantially less active, and/or inactive at other AVP receptors, such as the Vlb and/or V2 subtypes of AVP receptors.
• compounds described herein are 10-fold selective for the Via receptor compared to the Vlb and/or V2 receptor.
• compounds described herein are 100-fold selective for the Via receptor compared to the Vlb and/or V2 receptor.
• compounds described herein are 1000-fold selective for the Via receptor compared to the Vlb and/or V2 receptor.
• compounds described herein are 10,000-fold selective for the Via receptor compared to the Vlb and/or V2 receptor.
• compounds described herein are selectively active at the Via AVP receptor, and are less active, substantially less active, and/or inactive at other GPCRs.
• GPCRs G-protein coupled receptors
• compounds described herein are 10-fold selective for the Via receptor compared to other GPCRs. In another embodiment, compounds described herein are 100-fold selective , , ⁇ . . ..
• compounas aescr ea herein are 1000-fold selective for the Via receptor compared to other GPCRs.
• compounds described herein are 10,000-fold selective for the Via receptor compared to other GPCRs.
• compounds described herein, and pharmaceutical compositions and medicaments containing them have specific behavioral effects that are context dependent (see, for example, Ferris & Potegal Physiology and Behavior, 44:235-239 (1988)).
• compounds described herein, and pharmaceutical compositions and medicaments containing them have specific behavioral effects that are context dependent (see, for example, Ferris & Potegal Physiology and Behavior, 44:235-239 (1988)).
• compounds described herein, and pharmaceutical compositions and medicaments containing them have specific behavioral effects that are context dependent (see, for example, Ferris & Potegal Physiology and Behavior, 44:235-239 (1988)).
• compositions and medicaments containing them are effective in modulating neuropsychiatric disorders, but have little or no effect on sexual behavior.
• the formulae include and represent not only all pharmaceutically acceptable salts of the compounds, but also include any and all hydrates and/or solvates of the compound formulae. It is appreciated that certain functional groups, such as the hydroxy, amino, and like groups form complexes and/or coordination compounds with water and/or various solvents, in the various physical forms of the compounds. Accordingly, the above formulae are to be understood to be a description of such hydrates and/or solvates, including pharmaceutically acceptable solvates.
• the formulae include and represent each possible isomer, such as stereoisomers and geometric isomers, both individually and in any and all possible mixtures.
• the formulae include and represent any and all crystalline forms, partially crystalline forms, and noncrystalline and/or amorphous forms of the compounds.
• solvates refers to compounds described herein complexed with a solvent molecule. It is appreciated that compounds described herein may form such complexes with solvents by simply mixing the compounds with a solvent, or dissolving the compounds in a solvent. It is appreciated that where the compounds are to be used as pharmaceuticals, such solvents are pharmaceutically acceptable solvents. It is further appreciated that where the compounds are to be used as pharmaceuticals, the relative amount of solvent that forms the solvate should be less than established guidelines for such pharmaceutical uses, such as less than International Conference on Harmonization (ICH) Guidelines. It is to be understood that the solvates may be isolated from excess solvent by evaporation, precipitation, and/or crystallization. In some embodiments, the solvates are amorphous, and in other embodiments, the solvates are crystalline. ,, , , ⁇ , , , ⁇
• ihe compounds described herein may contain one or more cniral centers, or may otherwise be capable of existing as multiple stereoisomers. It is to be understood that in one embodiment, the invention described herein is not limited to any particular stereochemical requirement, and that the compounds, and compositions, methods, uses, and medicaments that include them may be optically pure, or may be any of a variety of stereoisomeric mixtures, including racemic and other mixtures of enantiomers, other mixtures of diastereomers, and the like. It is also to be understood that such mixtures of stereoisomers may include a single stereochemical configuration at one or more chiral centers, while including mixtures of stereochemical configuration at one or more other chiral centers.
• the compounds described herein may include geometric centers, such as cis, trans, E, and Z double bonds. It is to be understood that in another embodiment, the invention described herein is not limited to any particular geometric isomer requirement, and that the compounds, and compositions, methods, uses, and medicaments that include them may be pure, or may be any of a variety of geometric isomer mixtures. It is also to be understood that such mixtures of geometric isomers may include a single configuration at one or more double bonds, while including mixtures of geometry at one or more other double bonds.
• alkyl includes a chain of carbon atoms, which is optionally branched.
• alkenyl and alkynyl each include a chain of carbon atoms, which is optionally branched, and include at least one double bond or triple bond, respectively. It is to be understood that alkynyl may also include one or more double bonds.
• alkyl is advantageously of limited length, including C1-C24, C1-C12, Ci-Ce, Ci-C 6 , and C1-C4, and C2-C24, C2-C12, C2-C8, C2-C6, and C2-C4, and the like
• such particularly limited length alkyl groups including C1-C8, C1-C0, and C1-C4, and C2-C8, C2-C6, and C2-C4, and the like may be referred to as lower alkyl.
• alkenyl and/or alkynyl may each be advantageously of limited length, including C2-C24, C2-C12, C2-C8, C2-C6, and C2-C4, and C3-C24, C3-C12, C3-C8, C3-C6, and C3-C4, and the like
• alkenyl and/or alkynyl groups including C 2 -Cs, C2-C6, and C2-C4, and C3-C8, C3- C6, and C3-C4, and the like may be referred to as lower alkenyl and/or alkynyl.
• alkyl refers to alkyl as defined herein, and optionally lower alkyl.
• alkenyl refers to alkenyl as defined herein, and optionally lower alkenyl. In embodiments of the invention . . , , .
• alkynyi reters to alkynyl as defined herein, and optionally lower alkynyl.
• Illustrative alkyl, alkenyl, and alkynyl groups are, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-buty l, tert-butyl, pentyl, 2-penty 1, 3-pentyl, neopentyl, hexyl, heptyl, octyl, and the like, and the corresponding groups containing one or more double and/or triple bonds, or a combination thereof.
• alkylene includes a divalent chain of carbon atoms, which is optionally branched.
• alkenylene and alkynylene includes a divalent chain of carbon atoms, which is optionally branched, and includes at least one double bond or triple bond, respectively. It is to be understood that alkynylene may also include one or more double bonds. It is to be further understood that in certain embodiments, alkylene is advantageously of limited length, including C1-C24, C1-C12, Ci-Cs, Ci-C 6 , and C1-C4, and C2- C24, C2-C12, C2-C8, C2-C6, and C2-C4, and the like.
• alkylene groups including Ci-Cs, Ci-Ce, and C1-C4, and C2-C8, C2-C6, and C2-C4, and the like may be referred to as lower alkylene.
• alkenylene and/or alkynylene may each be advantageously of limited length, including C2-C24, C2-C12, C2-C8, C2-C6, and C2-C4, and C3-C24, C3-C12, C3-C8, C3-C0, and C3- C4, and the like.
• alkenylene and/or alkynylene groups including C2-C8, C2-C6, and C2-C4, and C3-C8, C3-C6, and C3-C4, and the like may be referred to as lower alkenylene and/or alkynylene. It is appreciated herein that shorter alkylene, alkenylene, and/or alkynylene groups may add less lipophilicity to the compound and accordingly will have different pharmacokinetic behavior.
• alkylene, alkenylene, and alkynylene refers to alkylene, alkenylene, and alkynylene as defined herein, and optionally lower alkylene, alkenylene, and alkynylene.
• Illustrative alkyl groups are, but not limited to, methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, sec-butylene, pentylene, 1,2-pentylene, 1,3-penty lene, hexylene, heptylene, octy lene, and the like.
• cycloalkyl includes a chain of carbon atoms, which is optionally branched, where at least a portion of the chain in cynch. It is to be understood that cycloalkylalkyl is a subset of cycloalkyl. It is to be understood that cycloalkyl may be polycyclic. Illustrative cycloalkyl include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, 2-methylcyclopropyl, cyclopentyleth-2-yl, adamantyl, and the like.
• cycloalkenyl includes a chain of carbon atoms, which is optionally branched, and includes at least one double bond, where at least a portion of the chain in cyclic. It is to be understood that the one or more double bonds may be in the cyclic portion of cycloalkenyl , . . . , mecanic . ⁇ . . , . .
• cycloalkyl may be poly cyclic.
• Illustrative cycloalkenyl include, but are not limited to, cyclopentenyl, cyclohexylethen-2-yl, cycloheptenylpropenyl, and the like.
• chain forming cycloalkyl and/or cycloalkenyl is advantageously of limited length, including C3- C24, C3-C12, C3-C8, C3-C6, and C5-C6. It is appreciated herein that shorter alkyl and/or alkenyl chains forming cycloalkyl and/or cycloalkenyl, respectively, may add less lipophilicity to the compound and accordingly will have different pharmacokinetic behavior.
• heteroalkyl includes a chain of atoms that includes both carbon and at least one heteroatom, and is optionally branched.
• Illustrative heteroatoms include nitrogen, oxygen, and sulfur. In certain variations, illustrative heteroatoms also include phosphorus, and selenium.
• cycloheteroalkyl including heterocycly l and heterocycle, includes a chain of atoms that includes both carbon and at least one heteroatom, such as heteroalkyl, and is optionally branched, where at least a portion of the chain is cyclic.
• Illustrative heteroatoms include nitrogen, oxygen, and sulfur.
• illustrative heteroatoms also include phosphorus, and selenium.
• Illustrative cycloheteroalkyl include, but are not limited to, tetrahydrofuryl, pyrrolidinyl, tetrahydropyranyl, piperidiny l, morpholinyl, piperazinyl, homopiperazinyl, quinuclidinyl, and the like.
• aryl includes monocyclic and poly cyclic aromatic carbocyclic groups, each of which may be optionally substituted.
• Illustrative aromatic carbocyclic groups described herein include, but are not limited to, phenyl, naphthyl, and the like.
• heteroaryl includes aromatic heterocyclic groups, each of which may be optionally substituted.
• Illustrative aromatic heterocyclic groups include, but are not limited to, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, quinolinyl, quinazolinyl, quinoxalinyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl,
• amino includes the group NH2, alkylamino, and dialkylamino, where the two alkyl groups in dialkylamino may be the same or different, i.e. alkylalkylamino.
• amino includes methylamino, ethylamino, dimethylamino, methylethylamino, and the like.
• amino modifies or is modified by another term, such as aminoalkyl, or acylamino the above variations of the term amino are included therein.
• aminoalkyl includes H 2 N-alkyl, methylaminoalkyl, ethylaminoalkyl, dimethy laminoalkyl, methylethylaminoalkyl, and the like.
• acylamino includes acylmethylamino, acylethylamino, and the like. . , ⁇ , , ⁇
• amino and derivatives thereof includes amino as described herein, and alkylamino, alkenylamino, alkynylamino, heteroalkylamino, heteroalkenylamino, heteroalkynylamino, cycloalkylamino, cycloalkenylamino,
• cycloheteroalkylamino cycloheteroalkenylamino, arylamino, arylalkylamino.
• amino derivative also includes urea, carbamate, and the like.
• hydroxy and derivatives thereof includes OH, and alkyloxy, alkenyloxy, alkynyloxy, heteroalkyloxy, heteroalkenyloxy, heteroalkynyloxy, cycloalkyloxy, cycloalkenyloxy, cycloheteroalkyloxy, cycloheteroalkenyloxy, aiyloxy, arylalkyloxy, arylalkenyloxy, arylalkynyloxy, heteroaryloxy, heteroarylalkyloxy,
• heteroarylalkenyloxy heteroarylalkynyloxy, acyloxy, and the like, each of which is optionally substituted.
• hydroxy derivative also includes carbamate, and the like.
• thio and derivatives thereof includes SH, and alkylthio, alkenylthio, alkynylthio, heteroalkylthio, heteroalkenylthio, heteroalkynylthio, cycloalkylthio, cycloalkenylthio, cycloheteroalkylthio, cycloheteroalkenylthio, arylthio, arylalkylthio, arylalkenylthio, arylalkynylthio, heteroarylthio, heteroarylalkylthio,
• thio derivative also includes thiocarbamate, and the like.
• acyl includes formyl, and alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, heteroalkylcarbonyl, heteroalkenylcarbonyl,
• heteroalkynylcarbonyl cycloalkylcarbonyl, cycloalkenylcarbonyl, cycloheteroalkylcarbonyl, cycloheteroalkenylcarbonyl, arylcarbonyl, arylalkylcarbonyl, arylalkenylcarbonyl, arylalkynvlcarbonyl, heteroarylcarbonyl, heteroarylalkylcarbonyl, heteroarylalkenylcarbonyl, heteroarylalkynylcarbonyl, acylcarbonyl, and the like, each of which is optionally substituted.
• carbonyl and derivatives thereof includes the group C(O), C(S), C(NH) and substituted amino derivatives thereof.
• carboxylic acid and derivatives thereof includes the group CO2H and salts thereof, and esters and amides thereof, and CN.
• sulfinic acid or a derivative thereof includes SO2H and salts thereof, and esters and amides thereof.
• sulfonic acid or a derivative thereof includes SC H and salts thereof, and esters and amides thereof.
• sulfony includes alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, heteroalkylsulfonyl, heteroalkenylsulfonyl, heteroalkynylsulfonyl, , . .. . , . . ⁇ , , , ⁇ ⁇ ⁇ .
• cycioalkylsulionyl cycloalkenylsullonyl, cycloheteroalkylsullonyl, cycloheteroalkenylsullonyl, arylsulfonyl, arylalkylsulfonyl, arylalkenylsulfonyl, arylalkynylsulfonyl, heteroarylsulfonyl, heteroarylalkylsulfonyl, heteroarylalkenylsulfonyl, heteroarylalkynylsulfonyl, acylsulfonyl, and the like, each of which is optionally substituted.
• hydroxylamino and derivatives thereof includes NHOH, and alkyloxylNH alkenyloxylNH alkynyloxylNH heteroalkyloxylNH
• heteroarylalkenyloxylNH heteroarylalkynyloxylNH acyloxy and the like, each of which is optionally substituted.
• hydrozino and derivatives thereof includes alkylNHNH, alkenylNHNH, alkynylNHNH, heteroalkylNHNH, heteroalkenylNHNH, heteroalkynylNHNH, cycloalkylNHNH, cycloalkenylNHNH, cycloheteroalkylNHNH, cycloheteroalkenylNHNH, arylNHNH, arylalkylNHNH, arylalkenylNHNH, arylalkynylNHNH, heteroarylNHNH, heteroarylalkylNHNH, heteroarylalkenylNHNH, heteroarylalkynylNHNH, acylNHNH, and the like, each of which is optionally substituted.
• optionally substituted includes the replacement of hydrogen atoms with other functional groups on the radical that is optionally substituted.
• Such other functional groups illustratively include, but are not limited to, amino, hydroxyl, halo, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, nitro, sulfonic acids and derivatives thereof, carboxylic acids and derivatives thereof, and the like.
• any of amino, hydroxyl, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, and/or sulfonic acid is optionally substituted.
• the terms "optionally substituted aryl” and “optionally substituted heteroaryl” include the replacement of hydrogen atoms with other functional groups on the aryl or heteroaryl that is optionally substituted.
• Such other functional groups illustratively include, but are not limited to, amino, hydroxy, halo, thio, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, nitro, sulfonic acids and derivatives thereof, carboxylic acids and derivatives thereof, and the like.
• any of amino, hydroxy, thio, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, and/or sulfonic acid is optionally substituted.
• Illustrative substituents include, but are not limited to, a radical -(CH2)xZ x , . n r , ⁇ . , . , . , .
• wnere ⁇ is an integer from 0-6 and Z A is selected from halogen, hydroxy, akanoyioxy, including Ci-Cs alkanoyloxy, optionally substituted aroyloxy, alkyl, including Ci-C 6 alkyl, alkoxy, including C1-C6 alkoxy, cycloalkyl, including C?-Cs cycloalkyl, cycloalkoxy, including C3-C8 cycloalkoxy, alkenyl, including C2-C6 alkenyl, alkynyl, including C2-C6 alkynyl, haloalkyl, including Ci-C 6 haloalkyl, haloalkoxy, including Ci-C 6 haloalkoxy, halocycloalkyl, including C3-C8 halocycloalkyl, halocycloalkoxy, including C3-C8 halocycloalkoxy, amino, Ci- C6 alkylamino, (
• alkyl)alkylcarbonylamino aminoalkyl, C1-C6 alkylaminoalkyl, (C1-C6 alkyl)(Ci-C 6 alkyl)aminoalkyl, alkylcarbonylaminoalkyl, N-(Ci-C6 alkyl)alkylcarbonylaminoalkyl, cyano, and nitro; or Z x is selected from -CO2R 4 and -CONR 5 R 6 , where R 4 , R 5 , and R 6 are each independently selected in each occurrence from hydrogen, Ci-C 6 alkyl, aryl-Ci-C6 alkyl, and heteroaryl-Ci-C 6 alkyl.
• prodrug generally refers to any compound that when administered to a biological system generates a biologically active compound as a result of one or more spontaneous chemical reach on(s), enzyme-catalyzed chemical reach on(s), and/or metabolic chemical reaction(s), or a combination thereof.
• the prodrug is typically acted upon by an enzyme (such as esterases, amidases, phosphatases, and the like), simple biological chemistry, or other process in vivo to liberate or regenerate the more pharmacologically active drug. This activation may occur through the action of an endogenous host enzyme or a non- endogenous enzyme that is administered to the host preceding, following, or during administration of the prodrug.
• prodrug use is described in U.S. Pat. No. 5,627,165. It is appreciated that the prodrug is advantageously converted to the original drug as soon as the goal, such as targeted delivery, safety, stability , and the like is achieved, followed by the subsequent rapid elimination of the released remains of the group forming the prodrug.
• Prodrugs may be prepared from the compounds described herein by attaching groups that ultimately cleave in vivo to one or more functional groups present on the compound, such as -OH-, -SH, -CO2H, -NR 2 .
• Illustrative prodrugs include but are not limited to carboxylate esters where the group is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, acyloxyalkyl, alkoxycarbonyloxyalkvl as well as esters of hydroxyl, thiol and amines where the group attached is an acyl group, an alkoxy carbonyl, aminocarbonyl, phosphate or sulfate.
• Illustrative esters, also referred to as active esters include but are not limited to 1-indanyl, N- oxysuccinimide; acyloxyalkyl groups such as acetoxymethyl, pivaloyloxymethyl,
• alkoxycarbonyloxyalkyl groups such as ethoxycarbonyloxymethyl, a-ethoxycarbonyloxyethyl, ⁇ -ethoxycarbonyloxyethyl, and the like; . . . . . . . . . . . . .
• ialKylaminoalKyl groups including di-lower alkylamino alkyl groups, such as
• prodrugs contain a chemical moiety, such as an amide or phosphorus group functioning to increase solubility and/or stability of the compounds described herein.
• a chemical moiety such as an amide or phosphorus group functioning to increase solubility and/or stability of the compounds described herein.
• Further illustrative prodrugs for amino groups include, but are not limited to, (C3-
• C2o)alkanoyl halo-(C3-C2o)alkanoyl; (C3-C2o)alkenoyl; (C4-C7)cycloalkanoyl; (C3-C0)- cycloalkyl(C2-Ci6)alkanoyl; optionally substituted aroyl, such as unsubstituted aroyl or aroyl substituted by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (Ci-C3)alkyl and (Ci-C3)alkoxy, each of which is optionally further substituted with one or more of 1 to 3 halogen atoms; optionally substituted aryl(C2- Ci6)alkanoyl and optionally substituted heteroaryl(C2-Ci6)alkanoyl, such as the aryl or heteroaryl radical being unsubstituted or substituted by 1 to 3 substituents selected
• prodrugs themselves may not possess significant biological activity, but instead undergo one or more spontaneous chemical reaction(s), enzyme- catalyzed chemical reaction(s), and/or metabolic chemical reaction(s). or a combination thereof after administration in vivo to produce the compound described herein that is biologically active or is a precursor of the biologically active compound.
• the prodrug is biologically active.
• prodrugs may often serves to improve drug efficacy or safety through improved oral bioavailability, pharmacodynamic half- life, and the like.
• Prodrugs also refer to derivatives of the compounds described herein that include groups that simply mask undesirable drug properties or improve drug delivery.
• one or more compounds described herein may exhibit an undesirable property that is advantageously blocked or minimized may become pharmacological, pharmaceutical, or pharmacokinetic barriers in clinical drug application, such as low oral drug absorption, lack of , , ,, site speciiicity, chemical instability, toxicity, and poor patient acceptance (baa taste, odor, pain at injection site, and the like), and others. It is appreciated herein that a prodrug, or other strategy using reversible derivatives, can be useful in the optimization of the clinical application of a drug.
• leaving group refers to a reactive functional group that generates an electrophilic site on the atom to which it is attached such that nucleophiles may be added to the electrophilic site on the atom.
• Illustrative leaving groups include, but are not limited to, halogens, optionally substituted phenols, acyloxy groups, sulfonoxy groups, and the like. It is to be understood that such leaving groups may be on alkyl, acyl, and the like. Such leaving groups may also be referred to herein as activating groups, such as when the leaving group is present on acyl.
• conventional peptide, amide, and ester coupling agents such as but not limited to PyBop, BOP-C1, BOP, pentafluorophenol,
• isobutylchloroformate and the like, form various intermediates that include a leaving group, as defined herein, on a carbonyl group.
• n is 0, or n is 1, or n is 2, etc.
• n is an integer from 0 to 8 also describes each and every subrange, each of which may for the basis of a further embodiment, such as n is an integer from 1 to 8, from 1 to 7, from 1 to 6, from 2 to 8, from 2 to
• the terms “treating”, “contacting” or “reacting” when referring to a chemical reaction generally mean to add or mix two or more reagents under appropriate conditions that allows a chemical transformation or chemical reaction to take place, and/or to produce the indicated and/or the desired product. It is to be understood that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added. In other words, there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
• composition generally refers to any product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. It is to be understood that the compositions described herein may be prepared from isolated compounds described herein or from salts, solutions, hydrates, solvates, and other , , ⁇ , , , ⁇ ⁇ ⁇ , , , , , .
• compositions may be prepared from various amorphous, non-amorphous, partially crystalline, crystalline, and/or other morphological forms of the compounds described herein. It is also to be understood that the compositions may be prepared from various hy drates and/or solvates of the compounds described herein. Accordingly, such pharmaceutical compositions that recite compounds described herein are to be understood to include each of, or any combination of, the various morphological forms and/or solvate or hydrate forms of the compounds described herein. In addition, it is to be understood that the compositions may be prepared from various co-crystals of the compounds described herein.
• compositions may include one or more carriers, diluents, and/or excipients.
• the compounds described herein, or compositions containing them may be formulated in a therapeutically effective amount in any conventional dosage forms appropriate for the methods described herein.
• the compounds described herein, or compositions containing them, including such formulations may be administered by a wide variety of conventional routes for the methods described herein, and in a wide variety of dosage formats, utilizing known procedures (see generally, Remington: The Science and Practice of Pharmacy, (21 st ed., 2005)).
• therapeutically effective amount refers to that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
• the therapeutically effective amount is that which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment.
• the total daily usage of the compounds and compositions described herein may be decided by the attending physician within the scope of sound medical judgment.
• the specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient: the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coinci dentally with the specific compound employed; and like factors well known to the researcher, veterinarian, medical doctor or other clinician of ordinary skill.
• the therapeutically effective amount is advantageously selected with reference to any , . , , . , strictly , . . , strictly , . . , . . . .
• the co-therapies described herein may allow for the administration of lower doses of compounds that show such toxicity, or other undesirable side effect, where those lower doses are below thresholds of toxicity or lower in the therapeutic window than would otherwise be administered in the absence of a cotherapy.
• an effective amount of any one or a mixture of the compounds described herein can be readily determined by the attending diagnostician or physician by the use of known techniques and/or by observing results obtained under analogous circumstances.
• determining the effective amount or dose a number of factors are considered by the attending diagnostician or physician, including, but not limited to the species of mammal, including human, its size, age, and general health, the specific disease or disorder involved, the degree of or involvement or the severity of the disease or disorder, the response of the individual patient, the particular compound administered, the mode of administration, the bioavailability characteristics of the preparation administered, the dose regimen selected, the use of concomitant medication, and other relevant circumstances.
• each compound of the claimed combinations depends on several factors, including: the administration method, the condition to be treated, the severity of the condition, whether the condition is to be treated or prevented, and the age, weight, and health of the person to be treated. Additionally, pharmacogenomic (the effect of genotype on the pharmacokinetic, pharmacodynamic or efficacy profile of a therapeutic) information about a particular patient may affect the dosage used.
• the individual components of a co-administration, or combination can be administered by any suitable means, contemporaneously, simultaneously, sequentially, separately or in a single pharmaceutical formulation.
• the number of dosages administered per day for each compound may be the same or different.
• the compounds or compositions may be administered via the same or different routes of administration.
• the compounds or compositions may be administered according to simultaneous or alternating regimens, at the same or different times during the course of the therapy, concurrently in divided or single forms.
• administering includes all means of introducing the compounds and compositions described herein to the host animal, including, but are not limited to, oral (po), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, inhalation, . .. . . . ... _. .
• compositions described herein may be administered in unit dosage forms and/or formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants, and/or vehicles.
• a therapeutically effective amount of one or more compounds in any of the various forms described herein may be mixed with one or more excipients, diluted by one or more excipients, or enclosed within such a carrier which can be in the form of a capsule, sachet, paper, or other container.
• Excipients may serve as a diluent, and can be solid, semi-solid, or liquid materials, which act as a vehicle, carrier or medium for the active ingredient.
• the formulation compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
• the compositions may contain anywhere from about 0.1% to about 99.9% active ingredients, depending upon the selected dose and dosage form.
• antagonist refers to a full or partial antagonist.
• the partial antagonists illustratively show at least about 50% antagonist effect, or at least about 80% antagonist effect.
• the term also includes compounds that are full antagonists of one or more vasopressin receptors. It is appreciated that illustrative methods described herein require therapeutically effective amounts of vasopressin receptor antagonists; therefore, compounds exhibiting partial antagonism at one or more vasopressin receptors may be administered in higher doses to exhibit sufficient antagonist activity to inhibit the effects of vasopressin or a vasopressin agonist.
• the effective use of the compounds, compositions, and methods described herein for treating or ameliorating one or more effects of a brain injury using one or more compounds described herein may be based upon animal models, such as murine, canine, porcine, and non-human primate animal models of disease.
• animal models such as murine, canine, porcine, and non-human primate animal models of disease.
• brain injuries in humans may be characterized by a loss of function, and/or the development of symptoms, each of which may be elicited in animals, such as mice, and other surrogate test animals.
• the mouse models described herein may be used to evaluate the methods of treatment and the pharmaceutical compositions described herein to determine the therapeutically effective amounts described herein.
• EXAMPLE Controlled cortical impact injury model. Briefly, test animals are initially anesthetized with isoflurane (4.5%), intubated, and mechanically ventilated with a gas mixture of N2O (66%), O2 (32%), and isoflurane (1.5-2.0%). Rectal temperature is maintained at 37.0 ⁇ 0.5°C using a self-adjusting heating pad. Catheters are placed into the femoral artery and vein. Mean arterial blood pressure (mABP) is monitored continuously using a data acquisition system, and arterial blood gas parameters (pH, pCh, pCC and plasma Na + concentration) are obtained at 15-min intervals.
• mABP Mean arterial blood pressure
• the femoral vein is used to administer vehicle, dimethyl sulfoxide (DMSO), or one or more compounds described herein.
• Animals are secured in a stereotactic frame.
• a mid-line scalp incision is made, and the skin and periosteum are retracted from the skull surface.
• a 10-mm-diameter craniotomy is made midway between Bregma and Lambda on the right side, 1-mm lateral to the midline.
• Injury is produced using a pneumatic impactor (e.g., 5 mm diameter) mounted at an angle (e.g. 10°) from the vertical plane.
• a single impact e.g.
• EXAMPLE Momentum exchange impact model. This model features several advantageous translational differences over some head injury models, such as the controlled cortical impact injury model. For example, the head, neck and body can move with impact, and the velocity of head movement and energy transfer can be calculated and scaled mild to provide range from moderate to severe concussions. Studies are conducted with moderate impacts with neuroradiological evidence of contusions. Male rats are concussed twice with one day.
• motor behaviors are assesea, using tor example, beam walk and/or rotarod tests.
• neuroradiological MRI is also performed.
• EXAMPLE Imaging Neuroanatomy.
• a high-resolution anatomical data set is collected using the RARE pulse sequence (20 slice; 1 mm; field of vision [FOV] 3.0 cm; 256 ⁇ 256; repetition time [TR] 2.5 sec; echo time [TE] 12.4 msec; NEX 6; 6.5-minute acquisition time).
• MSME multi-slice multi-echo
• T2 longitudinal relaxation time
• the T2 values are used for segmentation and quantification of the ventricle volume.
• the ventricle is identified as a hyperintensity on the T2 map over three 1 mm sections.
• the volume is calculated using a snake region growth algorithm in itk-SNAP (www.itksnap.org).
• the threshold is illustratively set at 6300 to 9000 as absolute pixel intensity. A point is seeded within the ventricle and the algorithm run until segmentation is complete.
• Preprocessing is illustratively accomplished by combining Analysis of Functional Neurolmages (AFNI_17.1.12, http://afni.nimh.nih.gov/afni/), FMRIB Software library (FSL, v5.0.9, http://fsl.fmrib.ox.ac.uk/fsl/), Deformable Registration via Attribute Matching and Mutual- Saliency Weighting (DRAMMS 1.4.1,
• Brain tissue masks for resting-state functional images are manually drawn using 3DSlicer (https://www.slicer.org/) and applied for skull-stripping. Normalization is completed by registering functional data to the MRI Rat Brain Template (Ekam Solutions LLC, Boston, MA) using affine registration through DRAMMS.
• the region-to-region functional connectivity . , , ,
• metno is illustratively perlormed to measure the correlations in spontaneous BULD
• a network is comprised of nodes and edges; nodes being the brain region of interest (ROI) and edges being the connections between regions.
• Nodes are defined using the ROIs segmented from an appropriate MRI RAT Brain Atlas.
• 171 nodes are defined.
• Voxel time series data are averaged in each node based on the residual images using the nuisance regression procedure.
• Pearson's correlation coefficients across all pairs of nodes (14535 pairs for 171 nodes) are computed for each subject among all three groups to assess the interregional temporal correlations.
• the r-values (ranging from -1 to 1) are z-transformed using the Fisher's Z transform to improve normality.
• 171 x 171 symmetric connectivity matrices are constructed with each entry representing the strength of edge.
• Group- level analysis is performed to look at the functional connectivity in controls, one hit and three hit groups.
• the resulting Z-score matrices from one-group t-tests are clustered using the - nearest neighbors clustering method to identify how nodes cluster together and form resting state networks.
• EXAMPLE Treatment in the momentum exchange impact model using compounds described herein.
• Male Sprague Dawley rats (n 19; 250-270g) aged 65 days, are obtained from Charles River (Worcester, MA).
• Test animals are maintained on a 12: 12 hour light: dark cycle with a lights on at 0700 hours and allowed access to food and water ad libitum.
• the protocols used in this study comply with the regulations of the Institutional Animal Care and Use Committee at the Northeastern University.
• the pneumatic pressure drive is replicated, 50g compactor, as described by Viano and reproduced consistently, the 7.4, 9.3, and 11.2 m/s impact velocities described for mild, medium, and severe head injury, respectively.
• the data described herein are obtained from a 9.12 meters/sec impact velocity, as determined using high-speed video recordings.
• a vehicle only control group (VCG) is administered saline. All administrations re administered to the Control and Treatment groups twice per day at 0700 and 1400 (IP @10mg/kg).
• the drug regimen is continued over the following 4 days (5 days total).
• the second head impact is delivered two days following the first on P72.
• Two . , , ⁇ ⁇ , , weeks post impact, animals are imaged and tested lor cognitive and motor benaviors. in an evaluations made, there was not a significant difference between the sham control group (CG) receiving test compounds and vehicle-only sham control group (VCG) receiving vehicle.
• CG sham control group
• VCG vehicle-only sham control group
• Concussed, untreated animals showed significant deficits in cognitive behavior, altered patterns of functional connectivity, and indices of anisotropy localized to the hindbrain and amygdala.
• Treatment group animals concussed and treated with Example 266 showed no deficits in learning and memory and there was not a significant difference compared to the sham Control group. Similarly, there was not a significant difference in overall motor behavior between Control and Treatment groups.
• Treatment group animals also showed enhanced functional connectivity, even compared to Control group in network circuitry associated with learning, cognition, memory, and attention.
• the compounds described herien may treat the cognitive and neurobiological effects of moderate to severe brain injury by not only reducing the inflammation and edema caused by the head injury, but by also promoting neuroadaptive changes in functional connectivity to compensate for the trauma.
• the Treatment group animals showed a hyperconnectivity even compared to Sham Control animals that were not injured, yet received treatment.
• the observed hyperconnectivity is relative to the default mode network represented by the control groups, where the Injury group show severe hypoconnectivity.
• the hyperconnectivity, resulting from treatment with the compounds described herein may reflect a reorganization of integrated neural networks that preserve function in response to brain injury.
• disrupted connectivity is an indication of diffuse axonal injury
• the results obtained herein for impact models, such as rmTBI are applicable to other brain injuries, including but not limited to traumatic brain injury, blast TBI, cerebral edema, chronic traumatic encephalopathy (CTE), subarachnoid hemorrhage, stroke, ischemic stroke, concussion, and falls.
• CTE chronic traumatic encephalopathy
• IG Injury group
• CG Control group
• TG Treatment group
• FIG. 3 shows correlation matrices of 166 rat brain areas for resting state functional connectivity (rsFC) comparing the Injury group to the Treatment group.
• the brain areas with significant correlations often appear as clusters because they are contiguous in their neuroanatomy and function.
• the clusters include areas:
• J. Cerebellum & Medulla & Entorhinal CTX - (paramedian lobule, parafiocculus cerebellum, flocculus), (ventral subiculum, entorhinal ctx, ectorhinal ctx), (median , ⁇ , , , , , ,
• the diagonal line separates the different experimental groups, and the pixels locations are mirror images across the diagonal (Areas G and M marked with arrows for illustration). Areas A-P show highlighted clusters of brain regions that have functional relationships and illustrate the default mode network in the Control group (data not shown). The brain areas with significant correlations may also appear as clusters because they are contiguous in their neuroanatomy and function.
• the Pain group network shows hypoconnectivity
• the Treatment group network shows hyperconnectivity.
• the Injury group network also shows hypoconnectivity compared to the Control group (data not shown).
• the Treatment group network also shows hyperconnectivity compared to the Control group (data not shown).
• ventral hippocampus shows hypoconnectivity in the Injury group compared to the Control group (data not shown), whereas the Treatment group shows hyperconnectivity compared to Injury group and Control group.
• the specific network connections, including the Control group are shown in the table.
• FIG. 4A Injury group
• FIG. 4B Treatment group
• Hyperconnectivity is also observed in the Treatment group for key nodes of the ventral hippocampus and the temporal cortex.
• Resting state functional connectivity analysis is useful in identifying subtle alterations in traumatically injured brain organization linked to cognitive and emotional symptoms of brain injury.
• the loss of connectivity and clustering in the Injury group shortens the pathway length or aggregate neural connections, reducing the metabolic cost of signal transduction.
• the amygdala remains largely disconnected from the ventral hippocampus and adjacent areas.
• Hypoconnectivity is well-established to be strongly associated with cognitive impairment and neurodegeneration.
• Area G is associated with cognition, learning, and memory.
• retiect a reorganization ot integrated neural networks to preserve function in response to brain injury.
• the reticular activating system remains largely disconnected from the ventral hippocampus and adjacent areas.
• Hypoconnectivity is well-established to be strongly associated with cognitive impairment, memory, and attention.
• Area M is associated with cognition, learning, and memory.
• the hyperconnectivity observed in the Treatment group including compared to the Control group, may reflect a reorganization of integrated neural networks to preserve function in response to brain injury and provides a therapeutic benefit leading to recovery of function.
• FIG. 5 shows the volume of lateral ventricles at the level of impact (hippocampal fimbria/septum) calculated and compared ., . . , .
• EXAMPLE Human vasopression Via receptor binding assay.
• a cell line expressing the human Via receptor in CHO cells (henceforth referred to as the hVi a cell line) was obtained from Dr. Michael Brownstein, NIMH, Bethesda, MD, USA.
• the hVia cDNA sequence is described by Thibonnier et al, Journal of Biological Chemistry, 269, 3304-3310 (1994), and the expression method was the same as described by Morel et al. (1992).
• the hVia cell line was grown in alpha-MEM with 10% fetal bovine serum and 250ug/ml G418 (Gibco, Grand Island, NY, USA).
• 990 ⁇ binding buffer containing InM 3H-AVP was added, and followed by 10 ⁇ series diluted Example compounds dissolved in DMSO. All incuba
• Binding affinities (IC50) and inhibition constants (Ki) for illustrative compounds are shown in the following Table.
• Vlb vasopressin receptor gene Proc. Natl. Acad. Sci. U S A. 92:6783-7 (1995); de Keyzer et al., "Cloning and characterization of the human V3(Vlb) pituitary vasopressin receptor” FEBS Lett. 356:215-20 (1994); Sugimoto et al, "Molecular cloning and functional expression of a cDNA encoding the human Vlb vasopressin receptor" J Biol. Chem. 269:27088-92 (1994)) was inserted into a mammalian cell expression vector PCI-neo (Promega) at EcoRl site.
• the recombinant plasmid carrying hVlb cDNA was identified from transformed E. Coll clones and used for the transfection of Chinese hamster ovary cell (CHO-Kl, ATCC). Two micrograms of hVlb receptor DNA was introduced into 10 5 CHO cells cultured in 6-well plate, using Fugene-6 mediated transfection technique (Boehringer Mannheim). Twenty -four hrs post transfection, Cells were then cultured under selection of G-418 (0.25mg/ml) supplemented to the culture medium. Three days later, limited dilution was carried out to obtain single cell clones in 96-well plates. After a period of 2-weeks of growth, monoclones were expanded into two sets of 12- well plates.
• Vlb cell lines (cells expressing either the human or rat Vib receptor) were grown in alpha- MEM medium supplemented with 10% fetal bovine serum and 250ug/ml G418 (Gibco, Grand Island, NY) in 75 cm 2 flask.
• hVlb cells were dissociated with enzyme-free, PBS based cell dissociation solution (Specialty Media, Phillipursburg, NJ), following the manufacturer's protocol. Cells were plated into 12-well culture plates at a rate of one flask to 18 plates (rate should be adjusted according to the extent of confluency), and maintained in culture for 2-3 days.
• Via phosphatidylinositol turnover
• the physiological effects of vasopressin are mediated through specific G-protein coupled receptors.
• the VlaR is coupled to the Gq/Gii family of G proteins and mediates phosphatidylinositol turnover.
• the agonist or antagonist character of the compounds of the invention may be determined by their ability to inhibit vasopressin-mediated turnover of phosphatidylinositol by the procedure described in the following paragraphs. Illustrative compounds, Examples 35, 44, 88, 110, and 133, were tested in this assay and found to be vasopressin Via antagonists.
• EXAMPLE Inhibition of v asopressin Vib-mediated phosphatidylinositol turnover, a functional assay for antagonist activity.
• the physiological effects of vasopressin are mediated through specific G-protein coupled receptors.
• the vasopressin Vit> receptor is coupled to a G protein, which is coupled to cAMP.
• the agonist or antagonist character of the compounds described herein may be determined by their ability to inhibit vasopressin-mediated turnover of phosphatidylinositol by using conventional methods, including the procedure described in the following paragraphs.
• Cells expressing the human or rat Vib receptors are grown in alpha-modified minimal essential medium containing 10% fetal bovine serum and 0.25 mg/ml G418. Three days prior to the assay, near-confluent cultures are dissociated and seeded in 6-well tissue culture plates, about 100 wells being seeded from each 75 cm 2 flask (equivalent to 12: 1 split .
• Each well contains 1 ml of growth medium with 2 ⁇ of [ ⁇ ] myo-inositol (American
• Test agents and AVP were added separately as 5 in DMSO to 12x75 mm glass tubes containing 1 mL of assay buffer (Tyrode's balanced salt solution containing 50 mM glucose, 10 mM LiCl, 15 mM HEPES pH 7.4, 10 ⁇ phosphoramidon, and 100 ⁇ bacitracin).
• assay buffer Tetrachlorosulfate
• the order of incubations was randomized. Incubations were initiated by removing the prelabeling medium, washing the monolayer once with 1 mL of 0.9% NaCl, and transferring the contents of the assay tubes to corresponding wells. The plates were incubated for 1 hour at 37 °C.
• Incubations were terminated by removing the incubation medium and adding 500 ⁇ , of ice cold 5% (w/v) trichloroacetic acid and allowing the wells to stand for 15 min.
• Econo-Columns were packed with 0.3 mL of AG 1 X-8 100-200 formate form resin. Resin was mixed 1: 1 with water and 0.6 mL added to each column. Columns were then washed with 10 mL water. Scintillation vials (20mL) were placed under each column. For each well, the contents were transferred to a minicolumn, after which the well was washed with 0.5 mL distilled water, which was also added to the minicolumn. The columns were then washed twice with 5 mL of 5 mM myo-inositol to elute free inositol.
• a high salt capacity scintillation fluid such as Tru-Count High Salt Capacity or Packard Hionic-Fluor.
• Inositol lipids were measured by adding 1 mL of 2% sodium dodecyl sulfate (SDS) to each well, allowing the wells to stand for at least 30 min., and transferring the solution to 20 mL scintillation vials, to which 10 mL Beckman Ready Protein Plus scintillation fluid was then added. Samples were counted in a Beckman LS 3801 liquid scintillation counter for 10 min. Total inositol incorporation for each well was calculated as the sum of free inositol, inositol phosphates, and inositol lipids.
• Via competitivity of test agents consisted of concentration-response curves for AVP in the absence and presence of two or more concentrations of test agent.
• Experiments to test for Vib competition by test agents consist of concentration-response curves for AVP in the absence and presence of at least five concentrations of test agent. Data were fit to a competitive logistic equation
• Y is dpm of inositol phosphates
• B concentration of basal inositol phosphates
• M is the maximal increase in concentration of inositol phosphates
• A is the concentration of agonist (AVP)
• E is the EC50 for agonist
• D is the concentration of antagonist (test agent)
• K is the Ki for antagonist
• Q is the cooperativity (Hill coefficient).
• Compound Example 225 produces a dose-dependent suppression of the action of AVP with IC50 (2.68 nM) and Ki (0.05 nM). These values are consistent with high affinity binding of Example 225 and its inhibition of inositol lipid synthesis via the human Via receptor.
• EXAMPLE Pharmacokinetics. Compounds described herein are rapidly absorbed after oral administration. Compounds described herein cross the blood-brain-barrier and achieve therapeutically effective concentrations in the CNS. Compounds described herein may be dosed according to a wide variety of protocols, including but not limited to q.d., b.i.d., and the like. Compounds described herein exhibit dose-related increases in Cmax and AUC when dosed according to various protocols, including but not limited to q.d., b.i.d. For example, b.i.d. dosing shows a 1.7-fold accumulation and improved T1/2 for AVN246. vêt ⁇ ⁇ . , . , XAJVlPLE. General Synthetic Routes. Proximal amide approacn wnicn permits synthetic variation at the distal amide site; proximal amide is set first, followed by distal amide diversity by parallel synthesis.
• Distal amide approach which permits synthetic variations at the proximal site; distal amide is set first, followed by proximal amide diversity by parallel synthesis.
• a aitionai etails and alternative syntheses lor preparing compounds described nerein are described in U.S. patent No. 7,119,083, the disclosure of which are incorporated herein by reference in their entirety.
• the compounds described herein may be formulated and administered according to the processes described in U.S. patent No. 7,119,083. Additional details are described in Guillon, CD., et al., Azetidinones as vasopressin Via antagonists. Bioorg Med Chem, 15(5):2054-80 (2007).
• Example 1 (4(S)-phenyloxazolidin-2-on-3-yl)acetyl chloride.
• a solution of 1.0 equivalent of (4(S)-phenyloxazolidin-2-on-3-yl)acetic acid (Evans, U.S. Patent No. 4,665,171) and 1.3 equivalent of oxalyl chloride in 200 mL dichloromethane was treated with a catalytic amount of anhydrous dimethylformamide (85 ⁇ I milliequivalent of acetic acid derivative) resulting in vigorous gas evolution. After 45 minutes all gas evolution had ceased and the reaction mixture was concentrated under reduced pressure to provide the title compound as an off-white solid after drying for 2 h under vacuum.
• Example 1A (4(R)-phenyloxazolidin-2-on-3-yl)acetyl chloride.
• Example 1A was prepared following the procedure of Example 1, except that (4(R)-phenyloxazolidin-2-on- 3-yl)acetic acid was used instead of (4(S)-phenyloxazolidin-2-on-3-yl)acetic acid (see, Evans & Sjogren, Tetrahedron Lett. 26:3783 (1985)).
• Example IB Methyl (4(S)-phenyloxazolidin-2-on-3-yl)acetate.
• Example 1C Methyl 2-(4(S)-phenyloxazolidin-2-on-3-yl)propanoate.
• a solution of methyl (4(S)-phenyloxazolidin-2-on-3-yl)acetate (1 g, 4.25 mmol) in 10 mL of anhydrous THF at -78 °C was treated with 4.68 mL (4.68 mmol) of a 1 M solution of lithium bis(trimethylsilyl)amide in THF.
• the reaction mixture was stirred for 1 h. at about -70 °C before adding Mel (1.59 mL, 25.51 mmol).
• Example ID 2-(4(S)-Phenyloxazolidin-2-on-3-yl)propanoic acid.
• methyl 2-(4(S)-phenyloxazolidin-2-on-3-yl)propanoate (1 g, 4.01 mmol) in 35 mL of MeOH was added, at 0°C, 14.3 mL (12.04 mmol) of a 0.84 M solution of LiOH in water.
• the reaction mixture was then stirred for 3 h. at ambient temperature.
• the MeOH was removed by evaporation, the crude residue dissolved in CH2CI2 and treated with saturated aqueous NaCl.
• Example IE 2-(4(S)-Phenyloxazolidin-2-on-3-yl)propanoyl chloride.
• a solution of 1 equivalent of Example ID and 1.3 equivalent of oxalyl chloride in 200 mL CH2CI2 (150 mL / g of propanoic acid derivative) was treated with a catalytic amount of anhydrous DMF (85 / mmole of propanoic acid derivative) resulting in vigorous gas evolution. After 45 min., all gas evolution had ceased and the reaction mixture was concentrated under reduced pressure to provide the title compound as an off-white solid after drying for 2 h. under vacuum.
• Example 2 General procedure for amide formation from an activated ester derivative. N-Benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester a-(3- trifluoromethyl)benzylamide. A solution of N-benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester a-N-hydroxysuccinimide ester (1.95 g, 4.64 mmol, Advanced ChemTech) in 20 mL of dry tetrahydrofuran was treated with 0.68 mL (4.74 mmol) of 3-(trifluoromethyl)benzyl amine.
• Examples 2A-2C and 3-5 were prepared according to the procedure of Example 2, except that N-benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester a-N-hydroxysuccinimide . . . . . .
• Example 2A N-Benzyloxycarbonyl-L-aspartic acid ⁇ -t-butyl ester a-[4-(2- phenylethyl)]piperazinamide. N-benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester oc-N- hydroxysuccinimide ester (5.0 g, 12 mmoL Advanced ChemTech) and
• Example 2B N-Benzyloxycarbonyl-L-glutamic acid ⁇ - ⁇ -butyl ester a-(3- trifluoromethyl)benzylarnide.
• N-benzyloxycarbonyl-L-glutamic acid ⁇ -t-butyl ester a-N- hydroxysuccinimide ester (4.83 g, 11.1 mmol, Advanced ChemTech) and 3- (trifluoromethyl)benzylamine) 1.63 mL (11.4 mmol) gave 5.41 g (98%) of the title compound as an off-white solid; 3 ⁇ 4 NMR (CDCh) ⁇ 1.40 (s, 9H), 1.88-1.99 (m, 1H), 2.03-2.13 (m, 1H), 2.23-2.33 (m, 1H), 2.38-2.47 (rnJH), 4.19-4.25 (s, 1H), 4.46-4.48 (m, 2H), 5.05-5.08 (m, 2H), 5.67-5.72 (m, 1H
• Example 2C N-Benzyloxycarbonyl-L-glutamic acid ⁇ -t-butyl ester a-[4-(2- phenylethyl)]piperazinamide. N-benzyloxycarbonyl-L-glutamic acid ⁇ -t-butyl ester a-N- hydroxysuccinimide ester (5.0 g, 12 mmol.
• Example 5A N-[(9H-Fluoren-9-yl)methoxycarbonyl]-0-(benzyl)-D-serine t- Butyl ester. N-[(9H-Fluoren-9-yl)methoxycarbonyl]-0-(benzyl)-D-serine (0.710 g, 1.70 mmole) in dichloromethane (8 mL) was treated with /-butyl acetate (3 mL) and concentrated sulfuric acid (40 in a sealed flask at 0 °C. Upon completion (TLC), the reaction was quenched with of dichloromethane (10 mL) and saturated aqueous potassium bicarbonate (15 mL).
• Example 5B 0-(Benzyl)-D-serine /-Butyl ester.
• Example 5A (0.620 g, 1.31 mmol) in dichloromethane (5 mL) was treated with tris(2-aminoethyl)amine (2.75 mL) for 5 h.
• Example 6 General procedure for amide formation from a carboxylic acid. N- Benzy loxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester a-(3-trifluoromethyl)benzylamide. A solution of 1 g (2.93 mmol) of N-benzyloxycarbonyl-D-aspartic acid ⁇ - -butyl ester monohydrate (Novabiochem) in 3-4 mL of dichloromethane was treated by sequential addition of 0.46 mL (3.21 mmol) of 3-(trifluoromethyl)benzylamine, 0.44 g (3.23 mmol) of 1-hydroxy- 7-benzotriazole, and 0.62 g (3.23 mmol) of l-[3-(dimethylarnino)propyl]-3-ethylcarbodiirnide hy drochloride.
• reaction mixture was washed sequentially with a saturated aqueous sodium bicarbonate solution and witharg . , . , ⁇ ⁇ . . .
• Examples 7-7H were prepared according to the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced by the appropriate amino acid derivative, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine.
• Example 7 N-Benzyloxycarbonyl-D-glutamic acid ⁇ - ⁇ -butyl ester a-(3- trifluoromethyl)benzylamide. N-benzyloxycarbonyl-D-glutamic acid ⁇ - ⁇ -butyl ester (1.14 g, 3.37 mmol) and 0.53 mL (3.70 mmol, Novabiochem) of 3-(trifluoromethyl)benzylamine gave 1.67 g (quantitative yield) of Example 7 as an off-white solid. Example 7 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 7 A N-Benzyloxycarbonyl-L-glutamic acid a-f-butyl ester ⁇ -(4- cyclohexyl)piperazinamide.
• N-benzyloxycarbonyl-L-glutamic acid ⁇ - ⁇ -butyl ester (1.36 g, 4.03 mmol) and 0.746g (4.43 mmol) of 1-cy clohexylpiperazine gave 1.93 g (98%) of Example 7A as an off-white solid; 3 ⁇ 4 NMR (CDCh) ⁇ 1.02-1.12 (m, 5H); 1.43 (s, 9H), 1.60-1.64 (m, 1H); 1.80-1.93 (m, 5H); 2.18-2.52 (m, 8H); 3.38-3.60 (m,4H); 4.20-4.24 (m, 1H); 5.03-5.13 (m, 2H); 5.53-5.57 (m, 1H); 7.28-7.34 (m, 5H).
• Example 7E N-Benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester a-[N-methyl- N-(3-trifluoromethylbenzyl)]amide.
• Example 7F N-Benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester a-[(S)-l-(3- trifluoromethylphenyl)ethyl] amide. N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate (Novabiochem) (84 mg, 0.25 mmol) and 47 mg of (S)-l-(3- trifluoromethylphenyl)ethylamme gave 122 mg (quantitative yield) of Example 7F as an off- white solid.
• Example 7F exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 7G N-Benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester a-[(R)-l-(3- trifluoromethylphenyl)ethyl] amide. N-benzyloxycarbonyl-D-aspartic acid ⁇ - -butyl ester monohydrate (Novabiochem) (150 mg, 0.44 mmol) and 83 mg of (R)-l-(3- trifluoromethylphenyl)ethylamine gave 217 mg (quantitative yield) of Example 7G as an off- white solid.
• Example 7G exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 7H N-Benzyloxycarbonyl-D-glutamic acid a-methyl ester ⁇ -(3- trifluoromethyl)benzylamide. N-benzyloxycarbonyl-D-glutamic acid a-methyl ester (508 mg, 1.72 mmol) and 317 mg (1.81 mmol) of 3-(trifluoromethyl)benzylamine gave 662 mg (85%) of Example 7H as an off-white solid. Example 7H exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 8 General procedure for hy drogenation of a benzyloxycarbonyl amine. L-aspartic acid ⁇ -t-butyl ester a-(3-trifluoromethyl)benzylamide. A suspension of 2.23 g (4.64 mmol) of N-benzyloxycarbonyl-L-aspartic acid ⁇ -f-butyl ester a-(3- trifluoromethyl)benzylamide and palladium (5% wt. on activated carbon, 0.642 g) in 30 mL of methanol was held under an atmosphere of hydrogen until complete conversion as determined by thin layer chromatography (95:5 dichloromethane/methanol eluent). The reaction was filtered to remove the palladium over carbon and the filtrate was evaporated to give 1.52 g , . , , and the filtrate was evaporated to give 1.52 g , . , , and the filtrate was evaporated to give 1.52 g
• Examples 9-13P were prepared according to the procedure of Example 8, except that N-benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester a-(3-trifluoromethyl)benzylamide was replaced by the appropriate amino acid derivative.
• Example 9 L-aspartic acid ⁇ - ⁇ -butyl ester a-[4-(2-phenylethyl)]piperazinamide. N-benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester a-[4-(2-phenylethyl)]piperazinamide (5.89 g, 11.9 mmol) gave 4.24 g (98%) of Example 9 as an off-white oil; 3 ⁇ 4 NMR (CDCb): ⁇ 1.42 (s, 9H); 2.61-2.95 (m, 10H); 3.60-3.90 (m, 4H); 4.35-4.45 (m, IH); 7.17-7.29 (m, 5H).
• Example 12 11.50 mmol gave 4.28 g (99%) of Example 12 as an off- white oil; 3 ⁇ 4 NMR (CDCb) ⁇ 1.39 (s, 9H); 2.00-2.08 (m, IH); 2.38-2.46 (m, IH); 2.55-2.90 (m, 9H); 3.61-3.82 (m, 4H); 4.48-4.56 (m, IH); 7.17-7.26 (m, 5H).
• Example 13 D-glutamic acid ⁇ - ⁇ -butyl ester a-(3-trifluoromethyl)benzylamide. N-benzyloxycarbonyl-D-glutamic acid ⁇ - ⁇ -butyl ester a-(3-trifluoromethyl)benzylamide (1.667 g, 3.37 mmol) gave 1.15 g (94%) of Example 13 as an off-white oil; 3 ⁇ 4 NMR (CDCb) ⁇ 1.41 (s, 9H); 1.80-2.20 (m, 4H); 2.31-2.40 (m, 2H); 3.51-3.59 (m, IH); 4.47-4.49 (m, 2H); 7.39-7.52 (m, 4H); 7.71-7.79 (m, IH).
• Example 13 A L-glutamic acid ⁇ - ⁇ -butyl ester Y-(4-cyclohexyl)piperazinamide. N-Benzyloxycarbonyl-L-glutamic acid ⁇ - ⁇ -butyl ester y-(4-cyclohexyl)piperazinamide (1.93 g, 3.96 mmol) gave 1.30 g (93%) of Example 13A as an off-white oil; 3 ⁇ 4 NMR (CDCb) ⁇ 1.02- ⁇ ⁇ . ⁇ ⁇ . 1 ⁇ ⁇ ⁇ . 1 ⁇ ⁇ . ⁇ ⁇ ⁇ 1 ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
• Example 13E D-aspartic acid ⁇ - -butyl ester a- [N-methyl-N-(3 - trifluoromethylbenzyl)] amide. N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester a-[N- methyl-N-(3-trifluoromethylbenzyl)] amide (0.282 g, 0.57 mmol) gave 0.195 g (95%) of Example 13E as an off-white oil.
• Example 13E exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 13F L-aspartic acid ⁇ - ⁇ -butyl ester a-[4-(2- phenylethyl)]piperazinamide. N-benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester a-[4-(2- phenylethyl)]piperazinamide (5.89 g, 11.9 mmol) gave 4.24 g (98%) of Example 13F as an off- white oil; 3 ⁇ 4 NMR (CDCh): ⁇ 1.42 (s, 9H); 2.61-2.95 (m, 10H); 3.60-3.90 (m, 4H); 4.35-4.45 (m, IH); 7.17-7.29 (m, 5H).
• Example 13G D-aspartic acid ⁇ - ⁇ -butyl ester a-(3-trifluoromethyl)benzylamide.
• Example 131 L-glutamic acid ⁇ -t-butyl ester oc-[4-(2- phenylethyl)]piperazinamide. N-benzyloxycarbonyl-L-glutamic acid ⁇ -t-butyl ester o>[4-(2- phenylethyl)]piperazinamide (5.86 g, 11.50 mmol) gave 4.28 g (99%) of Example 131 as an off- white oil; 3 ⁇ 4 NMR (CDCb) ⁇ 1.39 (s, 9H); 2.00-2.08 (m, IH); 2.38-2.46 (m, IH); 2.55-2.90 (m, 9H); 3.61-3.82 (m, 4H); 4.48-4.56 (m, IH); 7.17-7.26 (m, 5H).
• Example 13J D-glutamic acid ⁇ -f-butyl ester a-(3-trifluoromethyl)benzylamide. N-benzyloxycarbonyl-D-glutamic acid ⁇ -t-butyl ester a-(3-trifluoromethyl)benzylamide (1.667 g, 3.37 mmol) gave 1.15 g (94%) of Example 13J as an off-white oil; 3 ⁇ 4 NMR (CDCb) ⁇ 1.41 (s, 9H); 1.80-2.20 (m, 4H); 2.31-2.40 (m, 2H); 3.51-3.59 (m, IH); 4.47-4.49 (m, 2H); 7.39-7.52 (m, 4H); 7.71-7.79 (m, IH).
• Example 13M D-aspartic acid ⁇ - ⁇ -butyl ester a-[(S)-l-(3- trifluoromethylphenyl)ethyl] amide. N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester a- [(S)-l-(3-trifluoromethylphenyl)ethyl]amide (120 mg, 0.24 mmol) gave 91 mg (91%) of Example 13M as an off- white oil, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 13N D-aspartic acid ⁇ - ⁇ -butyl ester a-[(R)-l-(3- trifluoromethylphenyl)ethyl] amide. N-benzyloxycarbonyl-D-aspartic acid ⁇ - -butyl ester o> ,
• Example 130 D-aspartic acid ⁇ - ⁇ -butyl ester a-[N-methyl-N-(3- trifluoromethylbenzyl)] amide. N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester a-[N- methyl-N-(3-trifluoromethylbenzyl)] amide (0.282 g, 0.57 mmol) gave 0.195 g (95%) of Example 130 as an off-white oil, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 13P D-glutamic acid a-methyl ester ⁇ -(3- trifluoromethyl)benzylamide.
• N-Benzyloxycarbonyl-D-glutamic acid a-methyl ester ⁇ -(3- trifluoromethyl)benzylamide (764 mg, 1.69 mmol) gave g (516mg, 96%) of Example 13P as an off-white oil, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 14 General procedure for formation of a 2-azetidinone from an imine and an acetyl chloride.
• Step 1 General procedure for formation of an imine from an amino acid derivative.
• a solution of 1 equivalent of an a-amino acid ester or amide in dichloromethane is treated sequentially with 1 equivalent of an appropriate aldehy de, and a dessicating agent, such as magnesium sulfate or silica gel, in the amount of about 2 grams of dessicating agent per gram of starting a-amino acid ester or amide.
• the reaction is stirred at ambient temperature until all of the reactants are consumed as measured by thin layer chromatography. The reactions are typically complete within an hour.
• the reaction mixture is then filtered, the filter cake is washed with dichloromethane, and the filtrate concentrated under reduced pressure to provide the desired imine that is used as is in the subsequent step.
• Step 2 General procedure for the 2+2 cycloaddition of an imine and an acetyl chloride.
• a dichloromethane solution of the imine (10 mL dichloromethane/l gram imine) is cooled to 0 °C.
• an appropriate amine typically triethylamine
• a dichloromethane solution of 1.1 equivalents of an appropriate acetyl chloride such as that described in Example 1 (10 mL dichloromethane/l gm appropriate acetyl chloride).
• the reaction mixture is allowed to warm to ambient temperature over 1 h and is then quenched by the addition of a saturated aqueous solution of ammonium chloride.
• the resulting mixture is partitioned between water and dichloromethane. The layers are separated and the organic layer is washed successively with IN hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride. The organic layer is dried over magnesium sulfate and concentrated under reduced . , , , , . , . . , . _ .
• CD/ORD dichroism/optical rotary dispersion
• Example 15 tot-Butyl [3(S)-(4(S)-phenyloxazohdin-2-on-3-yl)-4(R)-(2- styryl)azetidin-2-on-l-yl]acetate.
• the imine prepared from 4.53 g (34.5 mmol) glycine tot-butyl ester and cinnamaldehyde was combined with 2-(4(S)- phenyloxazolidin-2-on-3-yl) acetyl chloride (Example 1) to give 5.5 g (30%) of Example 15 as colorless crystals (recrystallized, «-chlorobutane); mp 194-195 °C.
• Example 16 General procedure for acylation of an azetidin-2-on-l-ylacetate.
• a solution of (azetidin-2-on-l-yl)acetate in tetrahydrofuran (0.22 M in azetidinone) is cooled to - 78 °C and is with lithium bis(trimethylsilyl)amide (2.2 equivalents).
• the resulting anion is treated with an appropriate acyl halide (1.1 equivlants).
• the reaction is quenched with saturated aqueous ammonium chloride and partitioned between ethyl acetate and water.
• the organic phase is washed sequentially with IN hy drochloric acid, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride.
• the resulting organic layer is dried (magnesium sulfate) and evaporated.
• the residue is purified by silica gel chromatography with an appropriate eluent, such as 3:2 hexane/ethyl acetate.
• Example 15 Using the procedure of Example 16, 9.0 g (20 mmol) of Example 15 was acylated with 4.2 g (20 mmol) of trichloroethylchloroformate to give 7.0 g (56%) of Example 17; mp 176-178 °C.
• Example 18 2(RS)-(to ⁇ -Butoxycarbonyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on- 3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 18A 2(RS)-(toi-Butoxycarbonyl)-2-[3(S)-(4(S)-phenyloxazolidin-2- on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l -yfjacetic acid N-(2-fluoro-3- trifluoromethylbenzyl)amide.
• Example 18A was prepared according to the procedure of , . .
• Example 18A was obtained as a white solid (140 mg, 41%), and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 19-25AF were prepared according to the procedure of Example 14, where the appropriate amino acid derivative and aldehyde were used in Step 1, and the appropriate acetyl chloride was used in Step 2.
• Example 19A 2(S)-(teri-Butoxycarbonylmethyl)-2-[3(R)-(4(R)- phenyloxazolidin-2-on-3-yl)-4(S)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 19A was prepared according to the method of Example 19 except that 2-(4(R)-phenyloxazolidin-2-on-3-yl) acetyl chloride (Example 1A) was used instead of 2-(4(S)-phenyloxazolidin-2-on-3-yl) acetyl chloride.
• Example 20 2(S)-(teri-Butoxycarbonylethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2- on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 22 2(S)-(tert-Butoxycarbonylethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2- on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l -yljacetic acid N-[4-(2-phenylethyl)]piperazinamide.
• Example 23 2(R)-(ieri-Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazohdin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 23A 2(R)-(fe ⁇ Butoxycarbonylmethyl)-2-[3(R)-(4(Kj- phenyloxazolidin-2-on-3-yl)-4(S)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 23 A was prepared according to the method of Example 23 except that 2-(4(R)-phenyloxazolidin-2-on-3-yl) acetyl chloride (Example 1A) was used instead of 2-(4(S)-phenyloxazolidin-2-on-3-yl) acety l chloride.
• Example 24 2(R)-(tert-Butoxycarbonylethyl)-2-[3(S)-(4(S)-phenyloxazolidin- 2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 25 2(S)-(teri-Butoxycarbonylethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2- on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(4-cyclohexyl)piperazinarnide.
• Example 1 The imine prepared from 2.58 g (5.94 mmol) of L-glutamic acid ⁇ - ⁇ -butyl ester a-(4- cyclohexyl)piperazinamide and cinnamaldehyde was combined with 2-(4(S)-phenyloxazolidin- 2-on-3-yl) acetyl chloride (Example 1) to give 3.27 g (94%) of Example 25 after flash column chromatography purification (95:5 dichloromethane/methanol); 3 ⁇ 4 NMR (CDCh) ⁇ 1.32 (s, 9H); 1.10-1.18 (m, IH); 1.20-1.31 (m, 2H); 1.38-1.45 (m, 2H); 1.61-1.66 (m, IH); 1.84-1.89 (m, 2H); 1.95-2.01 (m, IH); 2.04-2.14 (m, 3H); 2.20-2.24 (m, IH); 2.29-2.35 (m, IH); 2.85- 2.
• Example 25A rert-Butyl 2(S)-(2-(4-cyclohexylpiperazinylcarbonyl)ethyl)-2- [3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetate.
• the imine prepared from 1.282 g (3.63 mmol) of L-glutamic acid ⁇ - ⁇ -butyl ester ⁇ -(4- cyclohexyl)piperazinamide and cinnamaldehyde was combined with 2-(4(S)-phenyloxazolidin- . . . .
• Example 25A alter tlasn column chromatography purification (50:50 hexanes/ethyl acetate); 3 ⁇ 4 NMR (CDCh) 5 1.15-
• Example 25B 2(R)-(ter ⁇ -Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(2-fluoro-3- trifluoromethylbenzyl)amide.
• Example 25C 2(R)-(teri-Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazohdin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(S)-a- methylbenzyl] amide.
• Example 25D 2(R)-(te ⁇ Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazohdin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(R)-a- methylbenzyl] amide.
• Example 25E 2(R)-(teri-Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-methyl-N-(3- trifluoromethylbenzyl)amide.
• Example 25G 2(R)-(fer ⁇ Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazohdin-2-on-3-yl)-4(R)-(2'-methoxystyr-2-yl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 25H iert-Butyl (2R)-(Benzyloxymethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetate.
• the imine prepared from 0.329 g (1.31 mmol) of 0-(benzyl)-D-serine f-butyl ester (Example 5B) and
• Example 1 The imine prepared from 0.3 g (0.88 mmol) of L-aspartic acid ⁇ - ⁇ -butyl ester ⁇ -(4- cyclohexyl)piperazinamide and cinnamaldehyde was combined with 2-(4(S)-phenyloxazolidin- 2-on-3-yl) acetyl chloride (Example 1) to give 464 mg (80%) of Example 251 as a white solid after flash column chromatography purification (50:50 hexanes/ethyl acetate).
• Example 251 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 25J ferf-Butyl 3(R)-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-3- methyl-4(R)-(styr-2-yl)azetidin-2-on-l-yl]-3-[(3- trifluoromethyl)phenylmethylaminocarbonyl]propanoate.
• Example 25K 2(R)-(fe ⁇ Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(prop-l-enyl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 1 The imine prepared from 0.289 g (0.83 mmol) of D-aspartic acid ⁇ - ⁇ -butyl ester a-(3-trifluoromethyl)benzylamide and crotonaldehyde was combined with 2-(4(S)-phenyloxazolidin-2-on-3-yl) acetyl chloride (Example 1) to give 381 mg (76%) of Example 25K after flash column chromatography purification (99: 1 CH2Ch/MeOH); 3 ⁇ 4 NMR ⁇ , ,
• Example 250 Methyl 2(S)-(fe ⁇ Butoxycarbonylethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetate.
• the imine prepared from 433 mg (1.99 mmol) of L-glutamic acid ⁇ - ⁇ -butyl ester a-methyl ester and
• Example 25M fert-Butyl 2(S)-(methoxycarbonylethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetate.
• the imine prepared from 428 mg (1.97 mmol) of L-glutamic acid ⁇ - ⁇ -butyl ester a-methyl ester and
• Example 25P Methyl 2(S)-(m-Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetate.
• Example 25L 2(R)-(teri-Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(R)-l-(3- . , . , ⁇ ⁇ tnlluorometnylpheny)ethylJ amide.
• Example 1 The imme prepared irom 160 mg (0.44 mmol J ot u-aspartic acid ⁇ - ⁇ -butyl ester a-[(R)-l-(3-trifluoromethylpheny)ethyl]amide and cinnamaldehyde was combined with 2-(4(S)-phenyloxazolidin-2-on-3-yl) acetyl chloride (Example 1) to give 166 mg (55%) of Example 25L after flash column chromatography purification (70:30 hexanes/ EtOAc).
• Example 25L exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 25N 2(R)-(te ⁇ Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(S)-l-(3- trifluoromethylpheny)ethyl] amide.
• Example 1 The imine prepared from 120 mg (0.22 mmol) of D-aspartic acid ⁇ - ⁇ -butyl ester a-[(S)-l-(3-trifluoromethylpheny)ethyl]amide and cinnamaldehyde was combined with 2-(4(S)-phenyloxazolidin-2-on-3-yl) acetyl chloride (Example 1) to give 75 mg (50%) of Example 25N after flash column chromatography purification (70:30
• Example 25N exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 25Q Methyl 2(R)-(2-(3-triiluoromethylbenzyl)aminocarbonyl)ethyl)- 2-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetate.
• Example 1 The imine prepared from 517 mg (1.62 mmol) of D-glutamic acid a-methyl ester ⁇ -(3- trifluoromethyl)benzylamide and cinnamaldehyde was combined with 2-(4(S)- phenyloxazolidin-2-on-3-yl) acetyl chloride (Example 1) to give 527 mg (51%) of Example 25Q after flash column chromatography purification (50:50 hexanes/ EtOAc).
• Example 25Q exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 26 General procedure for hydrolysis of a ferf-butyl ester.
• a solution of teri-butyl ester derivative in formic acid typically 1 g in 10 niL, is stirred at ambient temperature until no more ester is detected by thin layer chromatography (dichloromethane 95% / methanol 5%), a typical reaction time being around 3 hours.
• the formic acid is evaporated under reduced pressure; the resulting solid residue is partitioned between dichloromethane and saturated aqueous sodium bicarbonate.
• the organic layer is evaporated to give an off-white solid that may be used directly for further reactions, or recrystallized from an appropriate solvent system if desired.
• Examples 27-34AE were prepared from the appropriate rert-butyl ester according to the procedure used in Example 26.
• Example 27 2(R,S)-(Carboxy)-2-[3(S)-(4(S)-phenyloxazohdin-2-on-3-yl)-4(R)- (2-styryl)azetidin-2-on-l-yl] acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 18 (0.30 g, 0.46 mmol) was hydrolyzed to give 0.27 g (quantitative yield) of Example 27 as an off-white solid; 3 ⁇ 4 NMR (CDCh) ⁇ 4.17-5.28 (m, 9H); 6.21-6.29 (m, IH), 6.68-6.82 (m, IH); 7.05-7.75 (m, 13H); 9.12-9.18 (m, IH).
• Example 28 2(S)-(Carboxymethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)- 4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-(3-tnfluoromethylbenzyl)amide.
• Example 28A 2(S)-(Carboxymethyl)-2-[3(R)-(4(R)-phenyloxazolidin-2-on-3- yl)-4(S)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 29 2(S)-(Carboxyethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)- 4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-(3-tnfluoromethylbenzyl)amide.
• Example 31 2(S)-(Carboxyethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)- 4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-[4-(2-phenylethyl)]piperazinamide.
• Example 31 was hvdrolyzed to give 0.352 g (quantitative yield) of Example 31 as an off-white solid; 3 ⁇ 4 NMR (CDCb) ⁇ 1.93-2.01 (m, IH); 2.07-2.36 (m, 6H); 2.82-2.90 (m,
• Example 23 (1.51 g, 2.27 mmol) was hydrolyzed to give 1.38 g (quantitative yield) of Example 32 as an off- white solid.
• Example 32A 2(R)-(Carboxymethyl)-2-[3(R)-(4(R)-phenyloxazolidin-2-on-3- yl)-4(S)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 23A (550 mg, 0.83 mmol) was hydrolyzed to give 479 mg (95%) of Example 32A as an off- white solid.
• Example 32A exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 33 2(R)-(Carboxyethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)- 4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 24 (0.604 g, 0.89 mmol) was hydrolyzed to give 0.554 g (quantitative yield) of Example 33 as an off-white solid.
• Example 34 2(S)-(Carboxyethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)- 4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-(4-cyclohexyl)piperazinamide.
• Example 25 (0.537 g, 0.80 mmol) was hydrolyzed to give 0.492 g (quantitative yield) of Example 34 as an .
• Example 34A 2(S)-(2-(4-Cyclohexylpiperazinylcarbonyl)ethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid.
• Example 25A 2(S)-(2-(4-Cyclohexylpiperazinylcarbonyl)ethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid.
• Example 25A 2(S)-(2-(4-Cyclohexylpiperazinylcarbonyl)ethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4
• Example 34B 2(R)-(Carboxymethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3- yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-(2-fluoro-3- trifluoromethylbenzyl)carboxamide.
• Example 34C 2(R)-(Carboxymethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3- yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-[(S)-a-methylbenzyl]amide.
• Example 34D 2(R)-(Carboxymethyl)-2-[3(S)-(4(S)-phenyloxazohdin-2-on-3- yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-[(R)-a-methylbenzyl] amide.
• Example 34E 2(R)-(Carboxymethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3- yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-methyl-N-(3-trifluoromethylbenzyl)amide.
• Example 34G 2(R)-(Carboxymethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3- yl)-4(R)-(2'-methoxy styr-2-yl)azetidin-2-on- 1 -yl] acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 34 2(S)-(2-(4-Cyclohexylpiperazinylcarbonyl)methyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid.
• Example 251 (737 mg, 1.12 mmol) was hydrolyzed to give 640 mg (95%) of Example 341 as an off-white solid.
• Example 341 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 34J 3(R)-[3(S)-(4(S)-Phenyloxazohdin-2-on-3-yl)-3-methyl-4(R)- (sryr-2-yl)azetidin-2-on-l-yl]-3-[(3-trifluoromethyl)phenylmethylaniinocarbonyl]propanoic acid.
• Example 34K 2(R)-(Carboxymethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3- yl)-4(R)-(propen-l-yl)azetidin-2-on-l-yl]acetic acid N-(3-trifluoromethylbenzyl)amide.
• 160 mg (0.27 mmol) of Example 25K was hydrolyzed to give 131 mg (90%) of Example 34K as an off-white solid.
• 3 ⁇ 4 NMR (CDCb) ⁇ 1.69 (dd, J l
• Example 34L 2(R)-(Carboxylmethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3- yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-[(R)-l-(3-trifluoromethylpheny)ethyl]amide.
• Example 25L (166 mg, 0.24 mmol) was hydrolyzed to give 152 mg (quantitative yield) of Example 34L as an off-white solid; and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 34M 2(S)-(Methoxycarbonylethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2- on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid.
• Example 25M (875 mg, 1.64 mmol) was hy drolyzed to give 757 mg (97%) of Example 34M as an off-white solid, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 34N 2(R)-(Carboxylmethyl)-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3- yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-[(S)-l-(3-trifluoromethylpheny)ethyl] amide.
• Example 25N (38.5 mg, 0.057 mmol) was hydrolyzed to give 35 mg (quantitative yield) of Example 34N as an off-white solid, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 340 2(S)-(teri-Butoxycarbonylethyl)-2-[3(S)-(4(S)-phenyloxazolidin- 2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid.
• Example 250 (97 mg, 0.18 mmol) was dissolved in methanol/tetrahydrofuran (2.5 mL/2 mL) and reacted with lithium hydroxide (0.85 mL of a 0.85M solution in water; 0.72 mmol) for 6 hours at room temperature.
• Example 340 was prepared as an off-white solid, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 34P 2(S)-(teri-Butoxycarbonylethyl)-2-[3(S)-(4(S -pnenyloxazoli in- 2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid.
• Example 25P 200 mg, 0.39 mmol was hydrolyzed according to the method used for Example 340 to give 155 mg (88%) of Example 34P as an off-white solid; and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 34Q 2(R)-(2-(3-trifluoromethylbenzyl)amino-l-ylcarbonyl)ethyl)-2- [3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid.
• Example 25Q (150 mg, 0.24 mmol) was hydrolyzed according to the method used for Example 340 to give 143 mg (97%) of Example 34Q as an off-white solid, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 36-42A shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ -t-butyl ester monohydrate was replaced with Example 27, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 43-86A shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 28, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 86B Example 63 (44 mg, 0.06 mmol) was dissolved in 4 mL dichloromethane and reacted with 3-chloroperoxybenzoic acid (12 mg, 0.07 mmol) until the reaction was complete as assessed by TLC (dichloromethane 94%/methanol 6%, UV detection). The reaction was quenched with aqueous sodium sulfite, the dichloromethane layer was washed with 5% aqueous sodium bicarbonate and distilled water. Evaporation of the dichloromethane layer afforded Example 86B as an off-white solid (35 mg, 78%), and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 121-132 shown in The following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 30, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 132A-132B shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 341, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 132C 2(S)-(te ⁇ Butoxycarbonylmethyl)-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl] acetic acid N-(4- cyclohexy l)piperazinamide.
• Example 132C was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - -butyl ester monohydrate was replaced with Example 34P, and 3-(trifluoromethyl)benzy l amine was replaced with 1-cyclohexyl- piperazine.
• Example 132C exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 133-134G shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 32, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 134H was prepared using the procedure of Example 134H
• Example 134H was obtained as an off-white solid (48 mg, 94%), and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 1341 2(R)-[[4-(Piperidinyl)piperidinyl]carboxymethyl]-2-[3(S)-(4(R)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 1341 was prepared using the procedure of Example 6, , ⁇ ⁇ , Budapest , , , .
• Example 222 2(R)-[[4-(Piperidinyl)piperidinyl]carbonylmethyl]-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(2-fluoro-3- trifluoromethylbenzyl)carboxamide.
• Example 222 was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ -t-butyl ester monohydrate was replaced with Example 34B, and 3-(trifluoromethyl)benzyl amine was replaced with
• Example 222 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 223. 2(R)-[[4-(Piperidinyl)piperidinyl]carbonylmethyl]-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(S)-oc- methylbenzyl] amide.
• Example 223 was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34C, and 3-(trifluoromethyl)benzyl amine was replaced with 4-(piperidinyl)piperidine;
• Example 223 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 224 was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34D, and 3-(trifluoromethyl)benzyl amine was replaced with 4-(piperidinyl)piperidine;
• Example 223 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 225 was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - -butyl ester monohydrate was replaced with Example 34E, and 3-(trifluoromethyl)benzyl amine was replaced with
• Example 223 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure; Calc'd for C43H48F3N5O5: C, 66.91 ; H, 6.27; N, 9.07; found. C, 66.68; H, 6.25; N, 9.01.
• Example 225 Hydrochloride salt.
• Example 225 (212.5 mg) was dissolved in 30 mL dry Et 2 0. Dry HCl gas was bubbled through this solution resulting in the rapid formation of an off-white precipitate. HCl addition was discontinued when no more precipitate was observed forming (ca. 5 minutes). The solid was isolated by suction filtration, washed twice with 15 mL of dry EtiO and dried to 213.5 mg (96% yield) of an off-white solid; Calc'd for C43H49CIF3N5O5: C, 63.89; H, 6.11; N, 8.66; CI, 4.39; found. C, 63.41 ; H, 5.85; N, 8.60; CI, 4.8b.
• Example 225 A 2(R)-[[4-[2-(piperidinyl)ethyl]piperidinyl]carbonylmethyl]-2- [3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(S)-a- methylbenzyl] amide.
• Example 225 A was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34C, and 3-(trifluoromethyl)benzyl amine was replaced with 4-[2- (piperidinyl)ethyl]piperidine.
• Example 225A exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 225B 2(R)-[[ 4-[2-(piperidinyl)ethyl]piperidinyl]carbonylmethyl]-2- [3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(R)- a-methylbenzyl] amide.
• Example 225B was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34D, and 3-(trifluoromethyl)benzyl amine was replaced with 4- [2- (piperidinyl)ethyl]piperidine.
• Example 225B exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 225C 2(R)-[[4-(Piperidinyl)piperidinyl]carbonylmethyl]-2-[3(S)- (4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(R)-l-(3- trifluoromethylpheny)ethyl] amide.
• Example 225C was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34L, and 3-(trifluoromethyl)benzyl amine was replaced with
• Example 225C exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 225D 2(R)-[[4-(Piperidinyl)piperidinyl]carbonylmethyl]-2-[3(S)- (4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-[(S)-l-(3- trifluoromethylpheny)ethyl] amide.
• Example 225D was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34N, and 3-(trifluoromethyl)benzyl amine was replaced with
• Example 225D exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 87-120E shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 29, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 120F Example 120F was prepared using the procedure of Example 86B, except that Example 63 was replaced with Example 110 to give an off -white solid (54.5 mg, 98%).
• Example 120F exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 120G 2(S)-(Methoxycarbonylethyl)-2-[3(S)-(4(S)-phenyloxazolidin- 2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3-trifluoromethylbenzyl)amide.
• Example 120G was prepared using the procedure of Example 6, except that N- benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34M, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 35 2(S)-[4-(2-phenylethyl)piperazinyl-carbonylethyl]-2-[3(S)-(4(S)- phenyloxazohdin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Examples 141-171 shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 172-221R shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ -f-butyl ester monohydrate was replaced with Example 34A. and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 135-140 shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 33, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine: all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 140A 2(R)-( 2-(3-trifluoromethylbenzyl)amino-l-ylcarbonyl)ethyl)-2- [3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(4- cyclohexy l)piperazinamide.
• Example 140A was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - -butyl ester monohydrate was replaced with Example 34Q, and 3-(trifluoromethyl)benzylamine was replaced with 1-cyclohexyl- piperazine, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Examples 226-230C shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34F, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 86C 2(S)-[[4-(Piperidinyl)piperidinyl]carbonymethyl]-2-[3(S)-(4(R)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 86C was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - -butyl ester monohydrate was replaced with Example 28A, and 3-(trifluoromethyl)benzyl amine was replaced with 4- (piperidinyl)piperidine, and exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 231 was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34G, and 3-(trifluoromethyl)benzyl amine was replaced with
• Examples 232-233A shown in the following table, were prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with Example 34H, and 3-(trifluoromethyl)benzyl amine was replaced with the appropriate amine; all listed Examples exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 37 (50 mg, 0.067 mmol) in tetrahydrofuran (4 mL) was treated sequentially with sodium hydride (4 mg, 0.168mmol) and methyl iodide (6 ⁇ ,, 0.094 mmol) at -78 °C. The resulting mixture was slowly warmed to ambient temperature, and evaporated. The resulting residue was partitioned between dichloromethane and water, and the organic layer _ , . . , , .
• Example 234A 4-(Piperidinyl)-piperidinyl 3(R)-[3(S)-(4(S)-phenyloxazolidin- 2-on-3-yl)-3-methyl-4(R)-(styr-2-yl)azetidin-2-on-l-yl]-3-[(3- trifluoromethyl)phenylmethylaminocarbonyl] propanoic acid.
• Example 6 Using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with the carboxylic acid of Example 34J and 3- (trifluoromethyl)benzyl amine was replaced with 4-(piperidinyl)piperidine, the title compound was prepared in quantitative yield; MS (m+H) + 772.
• Example 235 2(S)-[[(l-Benzylpiperidin-4-yl)amino]carbonylmethyl]-2-[3(S)- (4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-phenyleth-l-yl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 235 was prepared using the procedure of Example 8, except that N-benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester a-(3- trifluoromethyl)benzylamide was replaced with Example 63 (50 mg, 0.064 mmol) to give 40 mg (80%) of Example 235 as an off-white solid;
• Example 235 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure. , ⁇ r /rifi / 1 , , , . . 1 , , , .
• Example 236 was prepared using the procedure of Example
• Example 236 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 236A (2S)-[(4-cy clohexylpiperazinyl)carbonylethyl]-2-[3(S)-(4(S)- phenyloxazolidin-2-on-3-yl)-4(R)-(2-phenyleth-l-yl)azetidin-2-on-l-yl] acetic acid N-[(R)- l,2,3,4-tetrahydronaphth-l-yl]amide.
• Example 236A was prepared using the procedure of Example 8, except that N-benzyloxycarbonyl-L-aspartic acid ⁇ - ⁇ -butyl ester a-(3- trifluoromethyl)benzylamide was replaced with Example 215 (76 mg, 0.10 mmol) to give 69 mg (90%) of Example 236A as an off white solid.
• Example 236A exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 237 2(R)-[[4-(Piperidinyl)piperidinyl]carbonylmethyl]-2-[3(S)-(4(S)- phenyloxazohdin-2-on-3-yl)-4(R)-(propen-l-yl)azetidin-2-on-l-yl]acetic acid N-(3- trifluoromethylbenzyl)amide.
• Example 237 was prepared using the procedure of Example 6, except that N-benzyloxycarbonyl-D-aspartic acid ⁇ -f-butyl ester monohydrate was replaced with Example 34K, and 3-(trifluoromethyl)benzyl amine was replaced with 4- (piperidinyl)piperidine.
• Example 237 exhibited an 3 ⁇ 4 NMR spectrum consistent with the assigned structure.
• Example 6 was prepared using the procedure of Example 6, except that N- benzyloxycarbonyl-D-aspartic acid ⁇ - ⁇ -butyl ester monohydrate was replaced with the coresponding benzyl protected cycteine analog, and 3-(trifluoromethyl)benzyl amine was replaced with 4-[2-(piperid-l-yl)ethyl]piperidine.
• Step 1 N-fButyloxycarbonyl-(S)-(benzyl)-D-cysteine-[4-(2-(l- piperidyl)ethyl)]piperidinenamide.
• Step 3 Using the general procedures described herein, the imine prepared from (S)-(benzyl)-D-cysteine-[4-(2-(l-piperidyl)ethyl)]piperidinenamide, dihydrochloride (0.417 g, 0.90 mmole) and cinnamaldehyde, in the presence on triethylamine (0.26 mL, 1.87 mmole), was combined with 2-(4(S)-phenyloxazolidin-2-on-3-yl) acety l chloride (Example 1) to give 0.484 g (76%) of Example 238 as an off-white solid after recrytallization from

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (16)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (1)

Family

ID=65723435

Family Applications (1)

Country Status (14)

Cited By (5)

Families Citing this family (2)

Citations (3)

Family Cites Families (57)

• 2018
  • 2018-09-17 EP EP18855876.1A patent/EP3681871A4/en active Pending
  • 2018-09-17 JP JP2020515077A patent/JP2020534274A/ja active Pending
  • 2018-09-17 TW TW107132685A patent/TW201919625A/zh unknown
  • 2018-09-17 WO PCT/US2018/051331 patent/WO2019055913A1/en not_active Ceased
  • 2018-09-17 CN CN201880070936.8A patent/CN111295373B/zh active Active
  • 2018-09-17 BR BR112020005107-1A patent/BR112020005107A2/pt unknown
  • 2018-09-17 MX MX2020002762A patent/MX2020002762A/es unknown
  • 2018-09-17 AU AU2018333051A patent/AU2018333051B2/en active Active
  • 2018-09-17 CA CA3075759A patent/CA3075759A1/en active Pending
  • 2018-09-17 US US16/646,744 patent/US11628160B2/en active Active
  • 2018-09-17 KR KR1020207010875A patent/KR102790657B1/ko active Active
  • 2018-09-17 IL IL273228A patent/IL273228B2/en unknown
  • 2018-09-17 MY MYPI2020001313A patent/MY208313A/en unknown
• 2020
  • 2020-03-24 ZA ZA2020/01880A patent/ZA202001880B/en unknown
• 2023
  • 2023-04-17 US US18/135,225 patent/US20240115553A1/en not_active Abandoned
  • 2023-09-25 JP JP2023161532A patent/JP7699634B2/ja active Active

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events